40 Rec'd PCT/PTO 2 9 SEP 2000

FORM PTO 1390 (REV 11-98) U S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371	P01934US1
	U.S. APPLICATION NO. (If known, see 37 CFR 1.5) **09/647418**

INTERNATIONAL APPLICATION NO. PCT/US99/06799	INTERNATIONAL FILING DATES 30/03/1999	PRIORITY DATE CLAIMED 30 March 1998

TITLE OF INVENTION   Regulated Apoptosis Using Chemically Induced Dimerization of Apoptosis Factors

APPLICANT(S) FOR DO/EO/US   David M. Spencer, et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. [x] This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.

2. [ ] This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.

3. [ ] This express request to begin national examination procedures (35 U.S.C. 371 (f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371 (b) and PCT Articles 22 and 39(1).

4. [x] A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed.

5. [x] A copy of the International Application as filed (35 U.S.C. 371 (c)(2))

   a. [ ] is transmitted herewith (required only if not transmitted by the International Bureau).

   b. [ ] has been transmitted by the International Bureau.

   c. [x] is not required, as the application was filed in the United States Receiving Office (RO/US).

6. [ ] A translation of the International Application into English (35 U.S.C. 371 (c)(2)).

7. [x] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))

   a. [ ] are transmitted herewith (required only if not transmitted by the International Bureau).

   b. [ ] have been transmitted by the International Bureau.

   c. [ ] have not been made; however, the time limit for making such amendments has NOT expired.

   d. [x] have not been made and will not be made.

8. [ ] A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).

9. [x] An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).

10. [ ] A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. [ ] An Information Disclosure Statement under 37 CFR 1.97 and 1.98.

12. [ ] An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 & 3.31 is included.

13. [ ] A FIRST preliminary amendment.

[ ] A SECOND or SUBSEQUENT preliminary amendment.

14. [ ] A substitute specification.

15. [ ] A change of power of attorney and/or address letter.

16. [x] Other items or information: Article 34 Amendments, copy of Assignment & Small Entity form.

Express Mail #EK102712117US

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER
09/647418	PCT/US99/06799	P01934US1

17. [x] The following fees are submitted:	CALCULATIONS PTO USE ONLY

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) – (5)):

[ ] Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO . . . .

[ ] International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO . . . .

[ ] International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO . . . .

[x] International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) . . . . .

[ ] International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) . . . . .

ENTER APPROPRIATE BASIC FEE AMOUNT =	670.00	

Surcharge of _____ for furnishing the oath or declaration later than [ ] 20 [ ] 30 months from the earliest claimed priority date (37 CFR 1.492 (e)). | 0.00 |

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	60 - 20 =	40	x 9.00	360.00	
Independent claims	1 - 3 =	0	x 39.00	0.00	
MULTIPLE DEPENDENT CLAIM(s) (if applicable)			x 260.00	260.00	
TOTAL OF ABOVE CALCULATIONS =				1,290.00	
Reduction of ½ for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				645.00	
SUBTOTAL =				645.00	

Processing fee of _____ for furnishing the English translation later than [ ] 20 [ ] 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).   + | | |

TOTAL NATIONAL FEE =	645.00	

Fee for recording the enclosed assignment (37 CFR 1.21 (h)). Assignment must be accompanied by appropriate cover sheet (37 CFR 3.28, 3.31)   + ($40.00 per property). | 40.00 |

TOTAL FEES ENCLOSED =	$ 685.00	

	Amount to be: Refunded
	Charged

a. [x] A check in the amount of _____ 685.00 _____ to cover the above fees is enclosed.

b. [ ] Please charge my Deposit Account No. _____ - _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. [x] The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to my Deposit Account No. _____ 06-2375 _____ . A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Melissa D. Schwaller
Fulbright & Jaworski L.L.P.
1301 McKinney, Suite 5100
Houston, TX 77010-3095

Melissa D. Schwaller 9-29-00
Melissa D. Schwaller

46,089
REGISTRATION NUMBER

Filed or Issued:

For Title: Regulated Apoptosis Using Chemically Induced Dimerization of Apoptosis Factors

P01934US1

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) AND 1.27(d)) - NONPROFIT ORGANIZATION

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION ___Baylor College of Medicine___

ADDRESS OF ORGANIZATION ___One Baylor Plaza___

___Houston, TX 77030___

TYPE OF ORGANIZATION

☒ UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION

☐ TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501(a) AND 501(c)(3)

☐ NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA
(NAME OF STATE_____)
(CITATION OF STATUTE_____)

☐ WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501(a) AND 501(c)(3) IF LOCATED IN THE UNITED STATES OF AMERICA

☐ WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA IF LOCATED IN THE UNITED STATES OF AMERICA
(NAME OF STATE_____)
(CITATION OF STATUTE_____)

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9(e) for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code with regard to the invention entitled ___Regulated Apoptosis Using Chemically Induced Dimerization of Apoptosis Factors___ by inventor(s) _____ described in

☒ the specification filed herewith

☐ application serial no._____, filed _____

☐ patent no._____, issued _____

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization regarding the above identified invention.

If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(d) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27).

NAME_____
ADDRESS_____
☐ INDIVIDUAL   ☐ SMALL BUSINESS CONCERN   ☐ NONPROFIT ORGANIZATION

NAME_____
ADDRESS_____
☐ INDIVIDUAL   ☐ SMALL BUSINESS CONCERN   ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING ___W. Dalton Tomlin___

TITLE IN ORGANIZATION ___Senior Vice President and General Counsel___

ADDRESS OF PERSON SIGNING ___Baylor College of Medicin,___

___One Baylor Plaza, Houston, TX 77030___

SIGNATURE ___[signature]___ DATE ___9/29/2000___

Express Mail EK102712117US

IN THE INTERNATIONAL RECEIVING OFFICE
AT THE UNITED STATES PATENT OFFICE

In re PCT Application of

BAYLOR COLLEGE OF MEDICINE

International Application No.:   PCT/US99/06799

Internaitonal Filing Date: 30 March 1999

TITLE: REGULATED APOPTOSIS USING CHEMICALLY INDUCED

DIMERIZATION OF APOPTOSIS FACTORS

AMENDMENT UNDER ARTICLE 34(2)(b)

Assistant Commissioner for Patents
Box PCT
Attn: RO/US
Washington, D.C. 20231

Dear Sir:

In response to the communication dated November 8, 1999, please find enclosed the replacement drawing sheets 1-52 and a substitute specification pages, numbers 15, 16, 40, 41, 42, 44, and 57-63. These pages have been revised to correct the specification and drawings in accordance with the Examiner's request. The corrections are noted below:

Page 15, Figure 33 has been reinstated in the application, withdrawn from Table 2.

Page 16, Figure 41 has been reinstated in the application, withdrawn from Table 4.

Page 40, line 20, reference to Table 1 has been deleted and text revised to refer to Figure 28.

Page 41, line 1, reference to Table 1 has been deleted and text revised to refer to Figure 28; line 10, Table 2 has been deleted and text revised to refer to Figures 33 and 34.

Page 42, line 1, reference to Table 2 has been deleted and text revised to refer to Figures 33 and 34; line 20, reference to Table 3 has been deleted and text revised to refer to Figures 37-39.

Page 44, line 2, reference to Table 4 has been deleted and text revised to refer to Figures 41-45.

Pages 57-63 merely represent renumbered pages since the tables on pages 57-61 filed in the substitute specification on July 30, 1999 have now been incorporated in Figures 28, 33, 37, 41 and 46, which are submitted herewith.

The requested changes have been made with the exception to the correction for Figures 24, 26, and 50. Figures 24A-24F/52 and 26A-26J/52 were indeed included with the original application. They were on the reverse sides of Figures 23 and 25. The correction requested to Figure 50, but not made, was a change that was made in the drawing filed July 30, 1999, to comply with the communication mailed May 5, 1999. The Applicant feels in that case that it is not necessary to change the drawing to its state prior to the May 5, 1999 communication. Applicant states that the changes made in the enclosed drawings do not constitute the addition of new matter. No fees are believed due in connection with this submission, however, Applicant authorizes the charge of any required fees to Deposit Account No. 06-2375.

Respectfully submitted,

By: _Thomas D. Paul_
Thomas D. Paul. No. 32,714

Date: _6/20/00_
Fulbright & Jaworski L.L.p.
1301 McKinney, Suite 5100
Houston, Texas 77010-3095
Phone: (713) 651-5325

membranes. HeLa cells transiently transfected with cytoplasmic S-F$_v$2-Casp3-E (C), plasma membrane-localized M-F$_v$2-Casp3-E (D), mitochondria-localized Mas70$_{34}$-F$_v$2-Casp3-E (E), or nuclear N2-F$_v$2-Casp3-E (F) were fixed, stained with anti-HA antibodies and examined by confocal microscopy. Alternatively, control proteins were localized, including S-F$_v$2-E (G), M-F$_v$2-E (H), Bcl-x$_L$-E (I), or Gal4-VP16-E (J). In each case, cells shown are representative of several transfected cells.

Figure 27. Nuclear-targeted caspase-1, -3, and -8 trigger apoptosis. (A-B) Transient transfection assay was performed as above. (A and B) Cells received 2 μg SRα-SEAP plus 2 μg nuclear targeted caspases, including N2-F$_v$1-F$_{vls}$1-Casp1 (Δ), N2-F$_v$1-F$_{vls}$1-Casp3 (▲), N2-F$_v$1-F$_{vls}$1-Casp8 (■), or control construct N2-F$_v$1-F$_{vls}$1 (□). (C) Nuclear targeted caspase-3 functions efficiently. Cells received SRα-SEAP plus 4 μg (□) or 1 μg (Δ) S-F$_v$2-Casp3, 4 μg (■) or 1 μg (▲) N2-F$_v$2-Casp, or 1 μg S-F$_v$1-F$_{vls}$1 (O). (D) Nuclear targeted FADD$_{125}$ has reduced activity. Cells received reporter plasmid plus 2 μg S-F$_v$1-F$_{vls}$1-FADD$_{125}$ (■),N2-F$_v$1-F$_{vls}$1-FADD$_{125}$ (□), or N2-F$_v$1-F$_{vls}$1 (Δ).

Figure 28. A) miniprep gel of pAdTrack-CMV (9220bp); B) miniprep gel of pAdTrack-CMV, pSH1/S-E-F$_v$1-F$_{vls}$1-ICEst and pSH1/S-F$_{vls}$1-Yama-E;

Figure 29. A) Representation of pAdTrack-CMV; B) and C) Gel of miniprep check of pAdTrack-CMV-S-F$_{vls}$1-Yama-E .

Figure 30. A) Representation of pAdTrack-CMV; B), C) and D) Gel of miniprep check of pAdTrack-CMV-S-F$_v$1-F$_{vls}$1-ICEst.

Figure 31. A) Gel of miniprep check of pSH1/S-E-F$_v$1-F$_{vls}$1-ICEst and B) Representation of pSH1/S-E-F$_v$1-F$_{vls}$1-ICEst;

Figure 32. Representation of pSH1/S-F$_{vls}$1-Yama-E;

Figure 33. Outline of the Generation of ADV-GFP-CMV-Yama-E and ADV-GFP-CMV-E-ICE;

EXAMPLE 17

Construction of an adenovirus expressing a chemically inducible apoptosis factor.

The E-F$_v$2 YAMA-E construct described previously was placed under the control of the CMV promoter and inserted into an adenoviral recombination vector. The adenoviral recombination vector contained a copy of the D1 gene from adenovirus. The CMV promoter - E-F$_v$2-YAMA-E construct was inserted such that the F$_v$2 construct was flanked on both sides by nucleotide sequences from the E1 gene.

The plasmid was transfected into adenovirus infected cells and a recombinant adenovirus expressing the chemically inducible apoptosis factor was isolated and purified by standard methods.

Figure 19 A shows a plasmid map of the adenoviral recombination vector used to construct an adenovirus expressing E-F$_v$2-YAMA-E under control of the CMV promoter and incorporating the 16S splice junction to improve the efficiency of mRNA processing (Takabe, et al. Mol. Cell. Bio. 8:466-472, 1988). Panel B slows the results of a restriction analysis of the plasmid. Figure 20 A shows a plasmid map of the plasmid used to construct a recombinant adenovirus expressing E-F$_v$2-YAMA-E under the control of the SRα promoter. Panel B shows the results of a restriction analysis of the plasmid.

EXAMPLE 18

Construction of Additional Adenovirus Constructs Containing Conditional Caspase 1 or 3

I. Construction of pAdTrack-CMV-F$_{vls}$1-Yama-E (Fig. 28)

1. Digest pAdTrack-CMV (Fig. 29A) with Eco RV and Not I. Purify the 9.2 kb vector by agarose electrophoresis and GeneClean (Fig. 28 B).

2. Digest pSH1/S-F$_{vls}$1-Yama-E (Fig. 32) with Eco RI and Not I. Blunt the Eco RI end. Purify the 1.2 kb fragment by agarose electrophoresis and GeneClean.

3. Ligate the above two fragments and transform XL-1 Blue with the ligation. Chose several colonies, do Miniprep and check with Sal I, Not I + Eco RI, Hind III + Eco RI, Hind III + Xho I. See Figs. 29 B and 29 C.

II.   Construction of pAdTrack-CMV-E-F$_v$1-F$_{vls}$1-ICEst (See Fig. 28)

1.   Digest pAdTrack-CMV with Eco RV and Not I. Purify the 9.2 kb vector by agarose electrophoresis and GeneClean (Fig. 28 B).

2.   Digest pSH1/S-E-F$_v$1-F$_{vls}$1-ICEst (Fig. 31 B) with Eco RI and Not I. Blunt the Eco RI end. Purify the 2.2 kb fragment by agarose electrophoresis and GeneClean.

3.   Ligate the above two fragments and transform XL-1 Blue with the ligation. Chose several colonies, do Miniprep and check with Sal I, Not I + Eco RI, Hind III + Eco RI, Hind III + Xho I. See Figs. 30 B through 30 D.

III.   Generation of ADV-GFP-CMV-Yama-E (Figs. 33 and 34)

1.   Linearize 1 μg pAdTrack-CMV-F$_{vls}$1-Yama-E with Pme I. Purify it by phenol-chloroform extraction, ethanol precipitation and resuspend in 6 μl H2O.

2.   Mix it with 100 μg p AdEasy-1 (Fig. 35) (in 1 μl), Co-transform 20 μl E. coli BJ5183 competent cells with GenePulser at 2,500 V, 200 Ohms, 25 uFD.

3.   Pick up 20 smallest colonies. Do Miniprep and check with Pac I. Candidate clones usually yield a large fragment (near 30 kb), plus a smaller fragment of 3.0 kb or 4.5 kb.

4.   Re-transform the correct recombinant plasmids into XL-1 Blue. Midiprep with Qiagen kit.

5.   Transfect 293 cell by the recombinant plasmid with FuGene. 4μg DNA/6μl FuGene/well (6 well-plate). Check GFP expression with fluorescent microscope.

6.   Harvest the cells when 30% of them are detached. Spin down the cells; use the supernatant for next infection. Repeat infection for several rounds.

7.   Collect the cells, repeat freeze/thaw/vortex four times. Purify the virus by CsCl gradient centrifuge.

IV.   Generation of ADV-GFP-CMV-E-ICE (Figs. 33 and 34)

1.   Linearize 1 μg pAdTrack-CMV- E-F_v1-F_{vls}1-ICEst with Pme I. Purify it by phenol-chloroform extraction, ethanol precipitation and resuspend in 6 μl H_2O.

2.   Mix it with 100 μg p AdEasy-1 (Fig. 35 A) (in 1 μl), Co-transform 20 μl E. coli BJ5183 competent cells with GenePulser at 2,500 V, 200 Ohms, 25 uFD.

3.   Pick up 20 smallest colonies. Do miniprep and check with Pac I. Candidate clones usually yield a large fragment (near 30 kb), plus a smaller fragment of 3.0 kb or 4.5 kb.

4.   Re-transform the correct recombinant plasmids into XL-1 Blue. Midiprep with Qiagen kit.

5.   Transfect 293 cell by the recombinant plasmid with FuGene. 4μg DNA/6μl FuGene/well (6 well plate). Check GFP expression with fluorescent microscope.

6.   Harvest the cells when 30% of them are detached. Spin down the cells, use the supernatant for next infection. Repeat infection for several rounds.

7.   Collect the cells, repeat freeze/thaw/vortex four times. Purify the virus by CsCl gradient centrifuge.

V.   Construction of pShuttle-CMV-E-F_v1-F_{vls}1-ICEst (Figs. 37-39)

1.   Digest pShuttle-CMV (Fig. 39) with Eco RV and Not I. Purify the 7.4 kb vector by agarose electrophoresis and GeneClean.

2.   Digest pSH1/S-E-F_v1-F_{vls}1-ICEst with Eco RI and Not I. Blunt the Eco RI end. Purify the 2.2 kb fragment by agarose electrophoresis and GeneClean. Fig. 38.

3.   Ligate the above two fragments and transform XL-1 Blue with the ligation. Chose several colonies, do miniprep and check with Sal I and Eco RI.

VI.   Generation of ADV-CMV-E-ICE (Figs. 37-39)

EXAMPLE 20

Assay To Determine Effects of Using Different Viruses (Figs. 41-45)

(See Table 4 for a more detailed protocol).

1. Cells were plated in 24 well-plate, $2X10^4$ to $4X10^4$ cells/well in 1 ml media (RPMI 1640 for JD-2α, LNCaP and PC3 cells; DMEM for Tramp, T-C2 and T-C2G cells) with 5% FBS, and incubated until the cell number doubled.

2. Cells were infected with the virus at different MOI and incubated overnight.

3. AP1903, or FK 1012,or AP20187 was added at a final concentration of 50 nM and cultures were incubated 24 hours.

4. Cells were fixed with 1% glutaraldehyde for 15 min.; stained with 0.5% crystal violet for 20 min.; washed with H2O for 30 min.; air dried; resolved with 200-500 ul/well Soreson's Solution for 5 min.; transfered 60—100 μl to each well of 96-well plate and read OD at 570 nm. Results are shown in Figs 42-45.

EXAMPLE 21

Replication deficient (Δ E1) adenoviral vectors expressing green flourescent protein and conditional Caspase 1 (ICE) or Caspase 3 (YAMA) were engineered. These vectors independently express green fluorescent protein so that infected cells are easily identified by their green color under fluorescent microscopy. These vectors were tested for their ability to induce apoptosis *in vitro* in a SMC line derived from a patient with BPH upon administration of a non-toxic, lipid-permeable, divalent FK506 analog (AP1903).

40,000 JD-2a cells per well were plated in 24-well plates and infected at a multiplicity-of-infection (MOI) of ~25 with Adv-F_v1-YAMA, an adenoviral vector expressing CID-regulated YAMA. After 24 hours, culture media was changed to control media ± 50nM AP1903 for an additional 24 hours, and the cells were viewed under fluorescent microscopy. All of the cells incubated with virus and maintained in control media appeared green, and were clearly attached and viable, similar to non-fluorescent

44

REFERENCES

1. Moolten, F.L. (1986) *Cancer Res.* **46**, 5276-5281.

2. Culver, K.W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E.H. & Blaese, R.M. (1992) *Science* **256**, 1550-1552.

3. Matthews, T. & Boehme, R. (1988) *Rev. Infect. Dis.* **10 Suppl 3**, S490-S494.

4. Ogasawara, J., Suda, T. & Nagata, S. (1995) *J. Exp. Med.* **181**, 485-491.

5. Spencer, D.M., Belshaw, P.J., Chen, L., Ho, S.N., Randazzo, F., Crabtree, G.R. & Schreiber, S.L. (1996) *Current Biology* **6**, 839-847.

6. Liles, W.C., Kiener, P.A., Ledbetter, J.A., Aruffo, A. & Klebanoff, S.J. (1996) *J. Exp. Med.* **184**, 429-440.

7. Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T. & Nagata, S. (1993) *Nature* **364**, 806-809.

8. Belshaw, P.J., Spencer, D.M., Crabtree, G.R. & Schreiber, S.L. (1996) *Chem. Biol.* **3**, 731-738.

9. Smith, C.A., Farrah, T. & Goodwin, R.G. (1994) *Cell* **76**, 959-962.

10. Yuan, J. (1997) *Curr. Opin. Cell Biol.* **9**, 247-251.

11. Hengartner, M.O. (1997) *Nature* **388**, 714-715.

12. Kroemer, G. (1997) *Nat. Med.* **3**, 614-620.

13. Spencer, D.M., Wandless, T.J., Schreiber, S.L. & Crabtree, G.R. (1993) *Science* **262**, 1019-1024.

14. Spencer, D.M. (1996) *TIG* **12**, 181-187.

15. Crabtree, G.R. & Schreiber, S.L. (1996) *Trends. Biochem. Sci.* **21**, 418-422.

16. Duan, H., Chinnaiyan, A.M., Hudson, P.L., Wing, J.P., He, W.W. & Dixit, V.M. (1996) *J. Biol Chem* **271**, 1621-1625.

17. Rosen, M.K., Yang, D., Martin, P.K. & Schreiber, S.L. (1993) *JACS* **115**, 821-822.

18. Spencer, D.M., Graef, I., Austin, D.J., Schreiber, S.L. & Crabtree, G.R. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 9805-9809.

19. Northrop, J.P., Ullman, K.S. & Crabtree, G.R. (1993) *J. Biol Chem* **268**, 2917-2923.

20. Henkart, P.A. (1996) *Immunity* **4**, 195-201.

21. Boldin, M.P., Varfolomeev, E.E., Pancer, Z., Mett, I.L., Camonis, J.H. & Wallach, D. (1995) *J. Biol. Chem.* **270**, 7795-7798.

22. Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J.L., Schroter, M., Burns, K., Mattmann, C., Rimoldi, D., French, L.E. & Tschopp, J. (1997) *Nature* **388**, 190-195.

23. Deveraux, Q.L., Takahashi, R., Salvesen, G.S. & Reed, J.C. (1997) *Nature* **388**, 300-304.

24. Freiberg, R.A., Spencer, D.M., Choate, K.A., Duh, H.J., Schreiber, S.L., Crabtree, G.R. & Khavari, P.A. (1997) *J. Invest. Dermat.* **108**, 215-219.

25. Aggarwal, B.B., Singh, S., LaPushin, R. & Totpal, K. (1995) *FEBS Letters* **364**, 5-8.

26. Freiberg, R.A., Spencer, D.M., Choate, K.A., Peng, P.D., Schreiber, S.L., Crabtree, G.R. & Khavari, P.A. (1996) *J. Biol. Chem.* **271**, 31666-31669.

27. Veis, D.J., Sentman, C.L., Bach, E.A. & Korsmeyer, S.J. (1993) *J. Immunol* **151**, 2546-2554.

28. Pan, G., O'Rourke, K., Chinnaiyan, A.M., Gentz, R., Ebner, R., Ni, J. & Dixit, V.M. (1997) *Science* **276**, 111-113.

29. Boldin, M.P., Goncharov, T.M., Goltsev, Y.V. & Wallach, D. (1996) *Cell* **85**, 803-815.

30. Muzio, M., Chinnaiyan, A.M., Kischkel, F.C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J.D., Zhang, M., Gentz, R., Mann, M., Krammer, P.H., Peter, M.E. & Dixit, V.M. (1996) *Cell* **85**, 817-827.

31. Tewari, M., Quan, L.T., O'Rourke, K., Desnoyers, S., Zeng, Z., Beidler, D.R., Poirier, G.G., Salvesen, G.S. & Dixit, V.M. (1995) *Cell* **81**, 801-809.

32. Chinnaiyan, A.M., O'Rourke, K., Tewari, M. & Dixit, V.M. (1995) *Cell* **81**, 505-512.

33. Bauer, M.K., Wesselborg, S. & Schulze-Osthoff, K. (1997) *FEBS Lett.* **402**, 256-258.

34. Chinnaiyan, A.M., Chaudhary, D., O'Rourke, K., Koonin, E.V. & Dixit, V.M. (1997) *Nature* **388**, 728-729.

35. Zou, H., Henzel, W.J., Liu, X., Lutschg, A. & Wang, X. (1997) *Cell* **90**, 405-413.

36. Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S.M., Ahmad, M., Alnemri, E.S. & Wang, X. (1997) *Cell* **91**, 479-489.

37. Chinnaiyan, A.M., O'Rourke, K., Lane, B.R. & Dixit, V.M. (1997) *Science* **275**, 1122-1126.

38. Wu, D., Wallen, H.D., Inohara, N. & Nunez, G. (1997) *J Biol. Chem.* **272**, 21449-21454.

5   39. Boulikas, T. (1997) *Anticancer Research* **17**, 1471-1506.

What is claimed is:

1. A conditionally lethal molecule comprising a chemical inducer binding domain and an apoptosis inducing factor, wherein said apoptosis inducing factor is an apoptosis signal transducing factor.

2. A conditionally lethal molecule according to claim 1, wherein said
5   apoptosis inducing factor is an adaptor molecule.

3. A conditionally lethal molecule according to claim 1, wherein said apoptosis inducing factor is a protease.

4. A conditionally lethal molecule according to claim 1, wherein said apoptosis inducing factor is a caspase.

10   5. A nucleic acid molecule encoding the conditionally lethal molecule of any one of claims 1-4.

6. A nucleic acid molecule according to claim 5, further comprising a sequence coding for tissue specific expression operatively linked to a sequence coding for a conditionally lethal molecule.

15   7. A gene therapy vector comprising a nucleic acid sequence coding for the expression of a conditionally lethal molecule according to anyone of claims 1-4.

8. A gene therapy vector according to claim 7, further comprising a sequence coding for a therapeutic gene.

9. A gene therapy vector according to claim 7, further comprising a
20   sequence coding for tissue specific expression operatively linked to a sequence coding for a conditionally lethal molecule.

10.   A transgenic animal expressing a conditionally lethal molecule according to any one of claims 1-4.

11.   A method of making a transgenic animal comprising the step of micro-injecting a nucleic acid molecule encoding a conditionally lethal molecule according to any one of claims 1-4.

12.   A method of treating a disease comprising the step of administering a vector that encodes a conditionally lethal molecule according to any one of claims 1-4.

13.   A method according to claim 12, wherein the disease is a hyperproliferative disease.

14.   A method according to claim 13, wherein the hyperproliferative disease is a benign disease.

15.   A method according to claim 14, wherein the disease is a malignant disease.

16.   A method according to claim 12, wherein the disease is atherosclerosis.

17.   A method of causing regression of a tumor comprising transfecting cells of said tumor with a nucleic acid molecule encoding a conditionally lethal molecule according to any one of claims 1-4.

18.   A method according to claim 17 further comprising administering a CID.

19.   A method of causing a reduction in tumor size comprising transfecting cells of said tumor with a nucleic acid molecule encoding a conditionally lethal molecule according to any one of claims 1-4.

20.   A method according to claim 19 further comprising administering a CID.

21.   A method of causing a reduction in PSA levels comprising transfecting cells of a tumor with a nucleic acid molecule encoding a conditionally lethal molecule according to any one of claims 1-4.

22.   A method according to claim 21 further comprising administering a CID.

23.   A method of affecting the rate of cell proliferation caused by BPH comprising transfecting prostate cells with a nucleic acid molecule encoding a conditionally lethal molecule according to any one of claims 1-4.

24.   A method according to claim 23 further comprising administering a CID.

25.   A method of inducing apoptosis in a cell comprising transfecting said cell with a nucleic acid molecule encoding a conditionally lethal molecule according to any one of claims 1-4.

26.   A method according to claim 26 further comprising administering a CID.

27. A method for determining the biological role of a cell type, comprising transfecting a cell of said cell type with a nucleic acid molecule encoding a conditionally lethal molecule according to any one of claims 1-4 and administering a CID.

ABSTRACT OF THE DISCLOSURE

The present invention discloses artificial death switches (ADSs) based on chemically induced dimerization of the cysteine proteases, caspase-1 (ICE) and caspase-3 (YAMA). In both cases, aggregation of the target protein is achieved by a non-toxic, lipid-permeable, dimeric FK506 analog that binds to an attached FK506-binding protein (FKBP). The intracellular crosslinking of caspase-1 or caspase-3 is sufficient to trigger rapid apoptosis in a Bcl-x_L-independent manner, suggesting that these conditional pro-apoptotic molecules can bypass intracellular checkpoint genes, like Bcl-x_L, that limit apoptosis. Since these chimeric molecules are derived from autologous proteins, they should be non-immunogenic and thus ideal for long-lived gene therapy vectors. These properties should also make chemically-induced apoptosis (CIA) useful for developmental studies, for treating hyperproliferative disorders and for developing animal models to a wide variety of diseases.

F_V2 - CASP - 3						F_V2 - CASP 3/S163					
HOURS						HOURS					
8	4	2	1	.5	0	8	4	2	1	.5	0

100 nM

500 nM

FIG. 10

F_V2 - CASP - 3						F_V2 - CASP 3/S163					
AP1903 nM						AP1903 nM					
100	32	10	3.2	1	0	100	32	10	3.2	1	0

FIG. 11

FIG. 12

FIG. 13

FIG. 14

FIG. 15

FIG. 16

FIG. 17

FIG. 18

FIG. 12

FIG. 13

FIG. 14

FIG. 15

FIG. 16

FIG. 17

FK506

FK1012 - A
(n = 1)

FIG. 18

FIG. 1

FIG. 2

FIG. 3

FIG. 4

FIG. 5

FIG. 6

FIG. 7

FIG. 8

FIG. 9

F_V2 - CASP - 3						F_V2 - CASP 3/S163					
HOURS						HOURS					
8	4	2	1	.5	0	8	4	2	1	.5	0

100 nM

500 nM

FIG. 10

F_V2 - CASP - 3						F_V2 - CASP 3/S163					
AP1903 nM						AP1903 nM					
100	32	10	3.2	1	0	100	32	10	3.2	1	0

FIG. 11

FIG. 12

FIG. 13

FIG. 14

FIG. 15

FIG. 16

FIG. 17

FIG. 18

FIG. 19A

FIG. 19B

FIG. 20A

FIG. 20B

FIG. 21

FIG. 22

FIG. 23A

FIG. 23B

FIG. 24B

FIG. 24A

FIG. 24D

FIG. 24C

FIG. 25B

% RELATIVE SEAP ACTIVITY

FK1012 nM

FIG. 25A

% RELATIVE SEAP ACTIVITY

FK1012 nM

FIG. 25D

FIG. 25C

FIG. 25F

FIG. 25E

FIG. 26B

FIG. 26A

FIG. 26C

FIG. 26D

FIG. 26E

FIG. 26F

FIG. 26G

FIG. 26H

FIG. 26I

FIG. 26J

FIG. 27C

FIG. 27D

Generation of pAd Track-CMV~$F_{vls}1$-YM-E
And   pAdTrack-CMV ~E-F_v1-F_{vls}1-ICE st

1. Cut pAdTrack-CMV-with EcoRV+Not. I

    $1\mu g/2\mu l$ (pAd Track-CMV) + $1\mu l$ buffer H
    + $1\mu l$ EcoRV + $1\mu l$ Not I +H_2O $5\mu l$
    37°C, 2 hr

Figure 28A

E-F_v1-F_{vls}1-ICEst

2. Cut pSH1/S-F_{vls}1-YM-E with Not I+EcoRI
    (got 2.2Kb F_{vls}1-YM-E)   or
    $2\mu g/1.2\mu l$ (pSH$_t$/S$_2$ F_{vls}1-YM-E+ $2\mu l$ EcoRI
    +$2\mu l$ Buffer H. + H_2O 14.8 μl. 37°C, 1 hr.

$2\mu g/3.2\mu l$

12.8 H_2O

Blunt
+ $10\mu M$ dNTP $12\mu l$ ($10\mu M$/each)+$2\mu l$ Buffer B
    $14\mu l$ H_2O + 4U/$2\mu l$ Klenow, 25°C, 30min;+EDTA→10 min.
Inactivate Klenow by heating at 75°C, 10 min. phenol: chloroform extraction

then + $2\mu l$ Not I. 37°C, 1hr.

3. Run gel, cut bands, pool together,
    Gene Clean. Elute in $40\mu l$

4. Ligation

    Elutent $16\mu l$ + $2\mu l$ 10X ligation buffer
    + $2\mu l$ T4 ligase, 16°C, overnight

4. Transformation

5. Miniprep with Qiagen Kit

Figure 28B

FIG. 29A

pAD TRACK - CMV - S - Fvls1 - Ym - E

FIG. 29B

FIG. 29C

FIG. 30A

pAdTRACK-CMV
9220 bp

PacI 1
LITR
PA
GFP
CMV
PA
CMV

Kan
Ori

EcoRV 2350 ✓
XbaI 2356
HindIII 2362
XhoI 2368
NotI 2376 ✓
SalI 2383
KpnI 2390
BglII 2398

Bm 6307
PacI 6299

RI 5285
PmeI 5279

pAD TRACK - CMV - S - Fv1
- Fvls1 - ICEst

FIG. 30B

FIG. 30C

FIG. 30D

λHindIII
UNCUT
+ SalI
+ BamHI
+ HindIII + EcoRI
+ HindIII + XhoI

NotI + EcoRI
λHindIII

FIG. 32

Generation of Ad-GFP-CMV-YM-E
Ad-GFP-CMV-E-ICE

1.   Co-transform E. coli BJ SH3 with pAdEasy -1 and pAdTrack-CMV-$F_{vls}1$-YM-E or pAd Track-CMV-E-F_v1-$F_{vls}1$-ICE st.

        a.   Linearize the shuttle plamids with PmeI
                1μg of pAdTrack-CMV-$F_{vls}1$-YM-E
        or 1μg of pAdTrack-CMV-E-F_v1-$F_{vls}1$-ICEst
                + 1μl Buffer + $H_2O \rightarrow 9\mu$l, + 1μl PmeI
37°C, 2hr
phenol-chloroform extraction, ethanol precipitation and resuspend in 6μl H_2O

        b.   Co-transformation: with 100ng pAdEasy -1
                                  20μl of BJ5183
                                  2.0mm cuvettes
                        at 2,500V, 200 Ohms, 25 μFD

        c.   Selection:
                pick 10 smallest colonies, miniprep. check with PacI.
                Retransform-XL-1 Blue with the correct plasmid, miniprep, recheck
                    with Pac I. Midiprep.

        d.   Transfect 293 cells with FuGene.

                90% confluence 293 cells in G-well-plate
                4μg plasmid/6μl FuGene/well

Figure 33

FIG. 34

FIG. 35B

+ EcoRI + BamHI
UNCUT
HindIII λ -

MINIPREP
082498

PacI 1
BamHI 8
Ori
Amp

pAdEasy-1
33414 bp

Ad5dE1/3

EcoRI 27465
SpeI 27216

BamHI 21696

FIG. 35A

FIG. 36A

FIG. 36B

FIG. 36C

Generation of Ad-CMV-E-ICE

Construction of pshuttle-CMV-F_v1-$F_{vls}1$-ICEst
and Ad-CMV-E-ICE

1. Cut pshuttle-CMV with EcoRV+Not I
    1μg/2μl (pshuttle-CMV) + 1μl Buffer H
    + 1μl EcoRV + 1μl NotI + H_2O 5μl
    37°C, 2hr.

2. Cut pSH1/S-E-F_v1-$F_{vls}1$-ICEst with
    Not I + EcoRI (get E-F_v1-$F_{vls}1$-ICE st)

    3μg/4μl + 3μl Buffer H. + 3μl EcoRI
    +H_2O 21μl, 37°C, 1hr

Figure 37A

Blunt
+ 10μM dNTP 18μl (10μM/each) +3μl Buffer B
+ 3 μl H_2O + 7μl, T4 DNA polymerase, 25°C, 30 min
+EDTA→ 10 min, 75°C, 10 min
phenol: chloroform extraction (twice)
ethanol precipitation → 24μl H_2O

Then
+ 3μl Buffer H + 3μl Not I
37°C, 2hr

3. Run Gel. Cut bands, pool together
    GeneClean, Elute in 40μl H_2O

4. Ligation
    Elutant 16μl+2μl 10X ligation Buffer
    +2μl T4 Ligase, 25°C, overnight

Figure 37B

5. Transformation
6. Miniprep + Restriction Enzyme Cechking
7. Cut pshuttle-CMV-E-F_v1-$F_{vls}1$-ICEst with PmeI (1/5 of a miniprep), Cotransform
    E. coli BJ5183 with 100ng PAd Easy-1. Miniprep+pac I checking (Fig. 37 B)
8. Chose #2, retransform XL-I Blue, Miniprep, +pac I; Midiprep, +pac I checking
    (Fig. 37 A)

FIG. 38

FIG. 39B

λ HindIII
pshuttle - CMV
+ EcoRI
+ BamHI
+ EcoRI + BamHI
pshuttle
+ EcoRI
+ BamHI
+ EcoRI + BamHI

BglII 955
KpnI 961
SalI 967
NotI 974
XhoI 982
HindIII 988
XbaI 996
EcoRV 1002

PacI 1

CMV

LITR

PA

pShuttle-CMV
7462 bp

RIGHT ARM

LEFT ARM

PmeI 3521
EcoRI 3527

Kan

Ori

BamHI 4549
PacI 4541

FIG. 39A

Luciferase Assay To Determine the Effect of Different Plasmids

1. Cells were plated in 6 well-plate, $1X10^5$/ well in 3 ml media (RPMI 1640 for JD-2α cells, DMEM for 293 and 293-Z4 cells) with 5% FBS, and incubated for 24 hours.

2. Cells were transfected with 2 μg DNA each (pGL2, pTrack-ICE, pTrack-YAMA, pShuttle-ICE) and FuGene(1 μg DNA/2 μl) and incubated overnight.

3. AP1903, or FK 1012,or AP20187 was added at a final concentration of 50 nM and cultures were incubated 24 hours.

4. Cells were lysed and checked for luciferase activity on a luminometer.

8 JAN 99 AM 10:58   V. 1.1

MEAS. TIMES (S) :   15.0

SAMPLE			RLU	% C.V.	
	1	1	294		
	1	2	291		
MEAN			292	0.8	Control
	2	1	2681958		
	2	2	2769999		
MEAN			2725979	2.3	Control + pGL2
	3	1	208762		
	3	2	223711		
MEAN			216237	4.9	pGL2 + ICE
	4	1	22084		
	4	2	22859		
MEAN			22471	2.4	pGL2 + ICE + AP1903

Figure 40

Effect of Ad-GFP-Ice and YM on Prostate Cancer and BPH Smooth muscle cells
JD-2α, T-C$_2$, T-C2G, LNCaP-Adeno-YM or Adeno-ICE

1. Plating cells: 24 well-plate
    JD-2a -- 20000/well in 1ml RPMI 1640 Media (5%FBS)
    T-C$_2$ -- 10000/well in 1 ml DMEM Media (+5% FBS. 5%Nuserum, Insulin DHT)
    T-C$_2$G -- 10000/well in 1 ml DMEM Media (+5% FBS. 5%Nuserum, Insulin DHT)
    LNCaP–30000/well in 1ml RPMI 1640 Media (5%FBS)

    incubate JD 24 hrs   cell number doubling - 40000/well
    T-C$_2$, FC$_2$G-48 hrs.   - 40000/well
    LNCaP-72 hrs   - 60000/well

2. Infection:
    For JD: ICE 1x10^7 iu/ml   MOI 1   2   4   8   16
                              Add 4   8   16   32   65 μl
            YM 2x10^7 iu/ml   MOI 2.5 5   10   20   40
                                   5   10   20   40   80 μl

    For T-C$_2$ ICE 5x10^7 iu/ml   MOI 2.5 5   10   20   40
    + T-C$_2$G   add 2   4   8   16   32 μl
            YM 5x10^7 iu/ml   MOI 2.5 5   10   20   40
                              Add 2   4   8   16   32 μl
            YM ICE 5x10^7 iu/ ml MOI 2.5 5   10   20   40

    For LN Cap   3   6   12   24   48 μl

    After 4 hrs. Add AP 1903 →50nM. Incubate 24 hrs.

3. Fix with 1% Glutaraldehyde - PBS, 15';
    Stain 0.5% crystal violate, 20'
    Wash with H$_2$O, 30';
    Resolve with Sortson's Solution 200 μl/well, 5';
    Transfer 100 μl to each well of 96-well plate, Read OD at 570 nM.

Figure 41

FIG. 42

FIG. 43

FIG. 44

FIG. 45

Western Blot 1103-110498

293 wells; infected with Ad-YM or Ad-ICE
9% Resolving gel; tranfer -- 400mA, 2hrs

1:1000 α-HA11 -- 1st Ab.

1.   Ad-YM3
2.   "" ""   +1903(100nM)
3.   "" ""   +2D-DCB (100nM)
4.   "" ""   +Both
5.   Ad-ICE

6.   "" ""   +1903
7.   "" ""   +2-D-DCB
8.   "" ""   + Both
9.   Ad-YM4

10.   "" ""   +1903
11.   "" ""   +2-D-DCB
12.   "" ""   +Both

EXPRESSION AND ACTIVATION OF ICE AND YM

Figure 46

FIG. 47A   FIG. 47B   FIG. 47C

FIG. 48

FIG. 49

MOI:
AP1903
(50 nM)

DAY 0: INJECT 2 x 10^6
TRAMP - C2 CELLS (s.c.)

DAY 12: INJECT ~10^{10} pfu
ADV-GFP/F$_v$2-CASP1 (i.t.)

50 - 100 mm^3

DAY 16: INJECT 50µg
C.I.D (i.p.)

ANALYSIS: RESECT TUMOR, H&E, TUNEL, ANTI-GFP

FIG. 50

20X

no ICE
+ CID

FIG. 51A

20X

ICE
no CID

FIG. 51B

10X

ICE
no CID

FIG. 51C

40X

ICE
no CID

FIG. 51D

FIG. 52A

FIG. 52B

FIG. 52C

FIG. 52D

REGULATED APOPTOSIS USING CHEMICALLY INDUCED
DIMERIZATION OF APOPTOSIS FACTORS

BACKGROUND OF THE INVENTION

1.   Field of the Invention

5   The present invention is directed to the field of molecular biology and, in particular, the fields of regulated apoptosis and gene therapy.

2.   Description of the Related Technology

Over the past several years gene therapy has been evolving as a therapeutic option for numerous benign and malignant human diseases. Approaches to gene therapy fall into several

10   broadly defined categories including: gene replacement therapy for diseases caused by the absence or malfunction of a single gene; immune system activation and vaccine development; and conditionally lethal gene therapy also known as "suicide gene" therapy. An example of a commonly used conditionally lethal gene frequently used for gene therapy of malignant diseases is the thymidine kinase (tk) gene from *Herpes simplex* virus (HSV). As used in a

15   gene therapy application, the tk gene may be incorporated into a gene therapy and upon introduction of the gene therapy vector into a cell, a copy of the tk gene is introduced into the target cell. The presence of the tk gene renders the cells sensitive to the dideoxy nucleoside analog ganciclovir. When cells expressing tk are contacted with ganciclovir, the tk gene phosphorylates the nucleoside analog resulting in a form of the compound that can be further

20   processed and incorporated into elongating DNA, leading to chain termination (3). Cells lacking the tk gene do not process ganciclovir and thus are not affected. Other genes encoding different enzymatic activities have been used as suicide genes. These include the *E. coli* purine nucleoside phosphorylase E gene, which generates toxic purines, and the bacterial cytosine deaminase gene which converts 5-fluorocytosine to 5-fluorouracil. Both of these

25   genes function by the *in situ* conversion of a nucleoside analogue into a form that is incorporated into replicating DNA thereby interfering with the replication process. Other

1

conditionally lethal genes that have been employed in gene therapy applications include the *E. coli* nitroreductase gene (see Drabek, *et al.* Gene Therapy 4(2):93-100, 1997) that acts by converting the pro-drug CB 1954 into a cytotoxic DNA interstrand crosslinking agent and the hepatic cytochrome P450 2B1 (see Wei, *et al.* Human Gene Therapy 5(8):969-978, 1994) that

5   acts by converting the anticancer drug cyclophosphamide into a toxic DNA-alkylating agent.

A problem inherent in all of these systems is the toxic and/or mutagenic nature of the pro-drugs employed. In all of the systems just mentioned, the pro-drug, even prior to its conversion into the active form, can have deleterious effects on cells. As a result of this toxicity, these types of gene therapy systems are not appropriate unless the condition of the

10   patient warrants assuming the risks of therapy. Thus, these systems are completely inappropriate for treatment of benign hyperproliferative conditions. Notwithstanding these limitations, vectors incorporating these genes have been developed and tested on various tumor models.

An example of such use of the thymidine kinase gene is provided in U.S. Patent No.

15   5,631,236, issued to Woo, *et al.* which is specifically incorporated herein by reference. The Woo, *et al.* patent discloses a method for treating localized solid tumors and papillomas in an individual. The method disclosed by Woo, *et al.* comprises introducing a recombinant adenoviral vector containing the *Herpes simplex* virus thymidine kinase gene. Subsequently, the infected cells are treated with the drug ganciclovir resulting in the death of the cells

20   expressing thymidine kinase. Woo, *et al.* disclosed the use of their adenoviral construct for the treatment of various types of cancers and papillomas including colon carcinoma, prostate cancer, breast cancer, lung cancer, melanoma, hepatoma, brain, head and neck cancers.

One result that has emerged from these tests is the observation that it is not necessary to introduce a suicide gene into every tumor cell in order to effect reduction in tumor size. In

25   fact, the successful introduction of the suicide gene into a small fraction of the tumor cells may result in an overall regression of the tumor. This effect, the death of cells not expressing the suicide gene in response to the death of a small percentage of cells carrying this suicide gene, has been termed the "bystander effect." The bystander effect has been observed in a

2

wide variety of tumor model system such as rat glioma, mouse model of prostate cancer, a mouse model of squamous cell carcinoma and others.

The bystander effect has been observed, not only within the tumor into which the suicide gene has been transduced, but in tumors located distally to the transduced tumor. In a mouse model for squamous cell carcinoma, Wilson, *et al.* (Arch. Otolar. Head and Neck Surgery 122:746-749, 1996) induced tumors in mice by injection of UMSCC 29 cells (No. 29 cells) into both the left and right flanks of mice. The tumors were allowed to grow and the tumors in the left flanks were subsequently injected with cells producing a retrovirus expressing HSV-tk while the tumors in the right flanks were not treated. After two days were allowed for *in vivo* transduction of the HSV-tk gene into the tumor cell genome, treatment with ganciclovir was begun. The authors observed a regression in the tumors located in the untreated flank after the commencement of ganciclovir treatments. Thus, killing of tumors at one site can result in the killing of tumor cells at a distant location, even though the distant cells were not capable of converting ganciclovir into a lethal form.

Several explanations have been proposed for the bystander effect. First, the cells treated with the suicide gene may release some factor that is toxic to adjacent tumor cells. The factor might be produced in response to the infection or might be a metabolite of ganciclovir. This explanation does not appear to account for the distal effects recounted above. A second hypothesis is that, as a result of the apoptotic or necrotic process that commences upon the administration of ganciclovir, certain toxic substances might be released by the affected cells which results in the death of the adjacent cells. Once again it is difficult to explain distal effects in the context of this model. A third hypothesis is that the death of the infected cells somehow potentiates an immune response to the tumor cells, perhaps by inducing an immune response to a tumor-specific antigen. This model could explain the distal effects observed. One mechanism that is envisioned is the uptake of apoptotic or necrotic tumor cell components by antigen-presenting cells thereby inducing a cytotoxic T cell response to cells expressing the antigen (Albert Nature 392:86-89, 1998).

There is evidence that some immune component is required for the bystander effect. In a mouse model employing carcinoma cell line MC26, Gagandeep, *et al.* (Cancer Gene

3

Therapy 3(2): 83-88, 1996) observed almost total tumor regression in immunocompetent

BALB/c mice, but not in immunocompromised athymic BALB/c mice, when MC26 cells were

co-injected with a retroviral packaging line expressing a HSV-tk gene and subsequently

treated with ganciclovir. The immunological component may also provide protection against

5   subsequent challenge by cancer cells as shown by Hall, *et al.* (International Journal of Cancer

70:183-187, 1997). Subcutaneous tumors were induced in mice by the injection of RM-1

cells, a tumor cell line of prostate origin. The tumors were subsequently treated with a

replication deficient adenovirus expressing HSV-tk under the control of the RSV promoter,

followed by treatment with ganciclovir. After treatment with ganciclovir, tumors were

10 surgically removed and the mice were challenged by RM-1 cells injected into the tail vein.

The animals were subsequently sacrificed and the lungs analyzed for visible lung metastases.

A 40% reduction in lung colonization in the treatment group indicated the possible production

of a systemic, anti-metastatic activity following a single treatment with an adenovirus

expressing HSV-tk and ganciclovir. These results lead to the conclusion that it may be

15 possible to treat not only solid, single tumors with suicide gene therapy but also metastatic

conditions.

Despite the successes observed in these and other systems, several problems remain

with the suicide genes known in the art. A major problem is the xenogeneic nature of the

suicide gene itself. Suicide genes of the prior art are of bacterial or viral origin. This typically

20 results in the mounting of an immune response against cells expressing the suicide gene,

reducing the prospects for long-term expression and shifting the immune response from

putative tumor-specific antigens towards potentially immunodominant peptide epitopes of the

suicide genes themselves.

Another major limitation in the suicide genes of the prior art is the nature of their

25 cytotoxic activity. The suicide genes of the prior art are directed to interfering with DNA

replication/maintenance. For example, the herpes virus tk gene results in the production

within the cell of a nucleoside analogue which is incorporated into DNA and results in chain

termination. This means that the efficacy of the therapy is dependent entirely upon the

incorporation of the nucleoside analogue into the DNA of the target cell. While therapies

4

based on this have shown to be effective in cells that are rapidly replicating, *i.e.*, cancer cells, these types of methods are far less effective on non-replicating cells.

An additional complexity that has been observed in therapeutic modalities based on the suicide genes of the prior art is the variable nature of the effects of the suicide gene on

5   different cell types. Beck, *et al.* (Human Gene Therapy 6:1525-1530, 1995) tested the sensitivity of a variety of tumor cell types to the effects of herpes virus tk/ganciclovir mediated cell death. The amount of ganciclovir required and the length of exposure required to induce cell death was highly variable *in vitro*, and this variability was found to correlate with the *in vivo* effectiveness of the treatment. The time necessary to effect a substantial amount of cell

10   death varied from 6 to 22 days at high doses of ganciclovir. Even more variable results were obtained at a lower dose of ganciclovir with one cell line (ESB, figure 1) which was essentially immune to doses of ganciclovir up to 1 μg/mL. An additional difficulty was revealed by Beck's work. It took up to three weeks to obtain a high level of cell killing even at high doses of ganciclovir. This exposure to high doses of potentially toxic materials for protracted

15   periods of time may have significant side effects.

Despite the problems seen with the suicide genes of the prior art, they have found widespread acceptance and have been incorporated into a wide variety of therapeutic modalities. Gene therapy applications based on the herpes virus tk gene have been developed for prostate cancer, gliomas, head and neck squamous cell carcinomas, breast cancer, and a

20   host of solid tumors. These therapies have been tested in a variety of model systems and some have progressed to the point of evaluation in human patients. A protocol based on the delivery of herpes virus tk gene to prostate cancer using an adenovirus vector has been developed at Baylor College of Medicine and has completed phase I trials. Of the 18 patients tested, three demonstrated a greater than 50% drop in their serum prostate specific antigen

25   (PSA) levels and an additional six patients experienced a temporary stabilization in their previously rising PSA levels. Thus, in this limited trial, half of the patients treated experienced some amelioration of disease.

An alternative approach to suicide genes involves using endogenous cellular mechanisms. One example of such a method is the use of Fas-mediated apoptosis. Fas is a

member of the tumor necrosis factor receptor (TNFR) superfamily whose members can induce

pleiotropic responses, including proliferation, activation, differentiation and apoptosis,

depending primarily on their cytoplasmic signaling domains (reviewed in 9). The molecular

details of Fas-mediated apoptosis, schematically represented in Figure 1, are rapidly emerging

5   and frequently reviewed (10).

        With reference to Figure 1, the interaction of Fas with the Fas-ligand (FasL) leads to

the aggregation of Fas cytoplasmic death domains (DD) and increases the affinity of the Fas

DD for the DD of the adapter molecule, FAS-associating protein with death domain, FADD

(MORT1). FADD, in turn, interacts with the cysteine protease, caspase-8 (FLICE/MACH) or

10   related caspase-10, via conserved death effector domains (DEDs) found in both proteins.

Thus, Fas crosslinking leads to caspase-8 crosslinking and subsequent activation of the

apoptotic cascade.

        Like all caspases, caspase-8 is an aspartic acid-directed protease that is activated by

the proteolytic removal of its amino terminal pro-domain and by an additional internal

15   cleavage, producing a fully active molecule comprised of two p17 and two p12 subunits.

Probably via a mechanism involving transproteolysis, the aggregation of caspase-8 contributes

to its activation and the initiation of a protease cascade that includes caspase-1(ICE)-related

and caspase-3(YAMA/CPP32)-related enzymes, ultimately leading to the irreversible cleavage

of multiple pro-apoptotic targets.

20   The first step of the Fas-mediated apoptotic cascade is the multimerization of Fas.

This can be accomplished using anti-Fas antibodies or Fas ligand. Both of these reagents

react with the extracellular portion of Fas and result in multimerization, however, since they

can react with all cells expressing Fas, they cannot be used to selectively ablate specific

genetically altered cells.

25   The problem of specificity was overcome by constructing a genetically engineered

form of Fas that can be selectively dimerized in response to an exogenous ligand by chemically

induced dimerization, (CID). CID activation of the Fas-mediated apoptotic cascade is

described in WO 95/02684 and in U.S patent application Serial No. 08/093,499 and Serial No.

08/179,143. These three documents are specifically incorporated herein by reference. A schematic representation of this technique is presented in Figure 2.

With reference to Figure 2, a recombinant Fas molecule is constructed that lacks an extracellular domain. In addition, the cytoplasmic portion of the Fas molecule is engineered

5   to contain one or more copies of the immunophilin FK506 binding protein 12 (FKBP12). The FKBP12 domain binds with high affinity to the dimerization inducer and thus is referred to as a chemical inducer binding domain or CBD. Further, the recombinant Fas molecule is engineered to contain an N-terminal myristoylation sequence. When contacted with the dimerization inducer FK1012 (a dimeric form of FK506, the structure of which is presented in

10   Figure 18), the CBD portions of two Fas molecules bind to the same inducer molecule resulting in the aggregation of the Fas molecules. The result of this aggregation is the activation of the Fas-mediated apoptotic cascade as described above.

This methodology suffers from some important drawbacks. A first, major obstacle to the use of Fas-based conditionally lethal constructs is autotoxicity. In the absence of inducer,

15   the Fas constructs of the prior art are toxic to cells expressing them. This limits the amount of Fas construct than can be expressed in any given cell. Limiting the amount of Fas expressed may reduce the efficiency with which apoptosis is induced.

A further difficulty is presented by the endogenous control mechanisms that normally inhibit apoptosis. As the Fas constructs of the prior art initiate the apoptotic cascade at an

20   early point in the Fas-mediated apoptotic pathway, the effects of Fas induction are subject to the intracellular check points that limit apoptosis. Thus, even though addition of the CID results in the dimerization of the intracellular portion of Fas and causes the earliest events in the apoptotic cascade to occur, such as the association of FADD with Fas, the incipient apoptotic cascade may be stopped at a cellular check point before the apoptotic process is

25   completed. Many tumors, especially those resistant to standard chemotherapeutic or hormonal therapies, have been shown to up-regulate the expression of apoptosis inhibiting gene products such as Bcl-2. Thus, the presence of apoptosis inhibiting gene products is likely to limit the use of Fas-based constructs.

Another factor that may limit the utility of Fas-based constructs as gene therapeutics is

the requirement for additional, mitochondrial factors and proteins, including cytochrome c, for

activation of the most downstream members of the apoptotic protease cascade including

caspase-3, caspase-6, and caspase-7 (reviewed in 11). Also, the protease apoptosis inducing

5   factor (AIF) may be essential for the activation of the downstream members. Members of the

Bcl-2 family, like Bax or Bcl-x_L, are localized primarily in the mitochondria and help to

modulate the release of these additional factors. The release of the additional factors is

concomitant with an apoptosis-associated increase in the permeability of the mitochondrial

membrane (12). The requirement for these additional factors may decrease the efficiency with

10   which Fas-based constructs can induce apoptosis.

Despite these drawbacks, this system has been shown to be able to induce apoptosis in

non-proliferating cells including CD4$^+$CD8$^+$ thymocytes (4,5), differentiated neutrophils and

monocytes (6), and hepatocytes (7). This system also has the advantage that conditional Fas

alleles can be made from human proteins, minimizing potential immunogenicity (5,8).

15   The techniques described in the instant application have been developed to overcome

the problems and limitations of prior art gene therapy methods. By placing apoptosis inducing

factors under the conditional control of chemically inducible dimerization domains, the

difficulties experienced in prior art methods have been obviated. The ligand used to induce

dimerization is substantially non-toxic, thus eliminating the concerns raised by the use of toxic

20   pro-drugs. The chemically inducible apoptosis constructs of the present invention are non-

toxic as well, in contrast to the autotoxicity of Fas-based constructs seen in the prior art.

Additionally, and perhaps most importantly, the point of action of the constructs of the

present invention is downstream of the apoptosis inhibiting checkpoints, thus, after initiation

of the apoptotic cascade by chemically induced dimerization, the constructs of the present

25   invention will not be inhibited by the up-regulation of apoptosis checkpoint genes.

While there is an extensive body of literature describing the use of suicide gene therapy

protocols to treat malignant tumors, there are many fewer suicide gene therapy protocols for

the treatment of benign proliferative disorders such as benign prostate hyperplasia (BPH).

One reason for this is the inherently risky nature of the gene therapy protocols of the prior art

8

due to the toxicity of the molecules used. Since the condition is not life threatening, the use of a treatment modality with such large inherent risks is seldom warranted. In addition, the suicide gene therapy methods of the prior art are most effective against rapidly proliferating cells, such as those found in malignant tumors. In contrast, in most benign hyperproliferative

5   disorders, the rate of cell proliferation is lower than it is in malignant disorders making the suicide gene therapy protocols of the prior art even less appropriate. For example, the enlargement of the prostrate seen in BPH is not a result of increase in the proliferation rate of prostate cells, but rather results from a decrease in the rate of deletion of prostate cells by apoptosis. Thus, the suicide gene therapies of the prior art are not appropriate for use against

10   this condition.

BPH refers to the benign enlargement of the prostate that develops in the aging male. The change that occurs in the prostate with the development of BPH have been described in two distinct stages in the pathologic development of BPH. First, there is the development of nodules in the glandular tissue of the transition zone and in the periurethral region of the

15   prostate which can be seen as early as the fourth decade of life. The number of nodules increases linearly with age, while the size of individual nodules increases slowly. The second stage of BPH generally occurs between the late 7th and mid 8th decade of life. This stage is characterized by an abrupt increase in the mass of the individual nodules, which may result in clinically significant BPH. Autopsy studies have demonstrated that approximately 50% of

20   men have histologic evidence of BPH by age 60 and this percentage increases to 80% of men by age 80. At relatively young ages (less than 45 years), most men do not show any evidence of BPH.

BPH is the most common benign tumor in men and is an age related condition impacting significantly on the morbidity as well as the health care expenditures of the segment

25   of the population that is over 65 years of age. The number of Medicare patients who have symptomatic BHP in 1990 equated to 4,996,000 (this figure does not represent the number of patients who were treated). Assuming an equal prevalence rate, changing population demographics will result in approximately 8,536,000 people over age 65 to suffer from symptomatic BPH by the year 2020.

9

There are a number of currently available treatments for BPH. These range from extremely invasive procedures such as open prostatectomy, transurethral incision of the prostate, transurethral resection of the prostate and laser prostatectomy. Other less invasive procedures include the application of electromagnetic energy in the form of microwaves or

5   radio frequency waves, the application of high intensity focused ultrasound, the insertion of prostatic stents and prostatic balloon dilation. Currently there are several accepted pharmacological treatments including alpha blockade and androgen suppression. Notwithstanding the availability of treatment regimens, there still exists a need for a simple effective mechanism of treating this extremely prevalent condition. The present invention

10   provides a mechanism to treat malignant tumors, both localized and metastatic, as well as benign hyperproliferative disorders and disorders resulting from a decrease in apoptosis, such as BPH, using vectors that deliver chemically inducible, apoptosis inducing factors into cells.

SUMMARY OF THE INVENTION

It is an object of this invention to construct a conditionally lethal gene that can be

15   activated to cause apoptosis in a cell in which it is present.

It is an object of this invention to provide a conditionally lethal, apoptosis inducing gene suitable for use in gene therapy applications involving non-proliferating cells.

It is an object of this invention to construct a conditionally lethal gene that is non-toxic unless induced.

20   It is an object of this invention to construct a conditionally lethal, apoptosis inducing gene that does not require membrane localization.

It is an object of this invention to construct a conditionally lethal, apoptosis inducing gene that bypasses endogenous apoptosis control mechanisms.

It is an object of this invention to provide a gene therapy treatment for selectively

25   deleting specific cells.

It is an object of this invention to provide a gene therapy vector that expresses a chemically inducible apoptosis factor. The gene therapy vectors of the present invention may

10

comprise viruses, plasmids or nucleic acids. In preferred embodiments, the gene therapy vector is a virus selected from the group consisting of adenoviruses, herpes viruses, pox viruses, retroviruses and adeno-associated viruses.

It is an object of this invention to provide a recombinant adenovirus expressing an

5   apoptosis inducing, conditionally lethal gene.

It is an object of this invention to provide a treatment modality for treatment of both localized and metastatic tumors comprising a vector which delivers a chemically inducible, apoptosis inducing gene.

It is an object of this invention to provide a treatment modality for the treatment of

10   benign proliferative disorders and disorders in which there is a loss of naturally occurring apoptosis, including but not limited to benign prostate hyperplasia and atherosclerosis, comprising the delivery of a vector expressing a chemically inducible, apoptosis inducing gene.

It is an object of this invention to provide transgenic animals that express chemically

15   inducible apoptosis factors in specific cell types.

It is an object of this invention to provide a method of determining the biological role of a specific cell type.

These and other objects are accomplished by the construction of a recombinant, chemically inducible version of an intermediate factor involved in the apoptosis cascade.

20   Since many of the events in signaling are regulated by protein-protein interactions, signaling intermediates, as exemplified by caspases, are ideal candidates for designing conditionally lethal alleles based on chemically-induced dimerization (CID) (13-15).

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1.   Schematic representation of the Fas-mediated apoptosis cascade.

25   Figure 2.   Schematic representation of a conditional, chemically inducible Fas receptor.

Figure 3.   Schematic representation of the conditionally lethal genes of the present invention.

11

Figure 4.   Diagram showing the steps followed in constructing the recombinant molecules
             of the present invention.

Figure 5.   Graph of reporter enzyme activity secreted from cells transfected with various
             amounts of a caspase-1 construct.

5   Figure 6.   Graph of reporter enzyme activity secreted from cells transfected with various
                 amounts of a caspase-1 construct.

Figure 7.   Graph of reporter enzyme activity secreted from cells transfected with various
             caspase-3 constructs.

Figure 8.   Graph of reporter enzyme activity secreted from cells transfected with various
10   caspase-3 constructs.

Figure 9.   Graph of reporter enzyme activity secreted from cells transfected with various
             caspase-3 constructs.

Figure 10.   Western blot of cells transfected with various caspase-3 constructs and probed
             with anti-HA antibody.

15 Figure 11.   Western blot of cells transfected with various caspase-3 constructs and probed
                 with anti-HA antibody.

Figure 12.   Graph of reporter enzyme activity secreted from cells transfected with either a
             caspase-1 construct, a Bcl-x_L construct or co-transfected both caspase-1 and
             Bcl-x_L constructs.

20 Figure 13.   Graph of reporter enzyme activity secreted from cells transfected with either a
                 caspase-3 construct, a Bcl-x_L construct or co-transfected both caspase-3 and
                 Bcl-x_L constructs.

Figure 14.   Bar graph of reporter enzyme activity secreted from cells transfected with
             either a caspase-1 construct, a Bcl-x_L construct or co-transfected both

25   caspase-1 and Bcl-x_L constructs and treated with an anti-Fas antibody before
                 the assay was conducted.

Figure 15.   Bar graph of reporter enzyme activity secreted from cells transfected with
             either a caspase-3 construct, a Bcl-x_L construct or co-transfected both

12

caspase-3 and Bcl-x_L constructs and treated with an anti-Fas antibody before the assay was conducted.

domain (residues 179-319), and FADD$_{125}$ (death effector domain)), and
hemaglutinin epitope tag (E).

Figure 24.   Activation of caspase-1 and -8, but not -3, by high-specificity CID, AP1903,
5   requires a flexible linker between FKBP12 and caspase domains. (A-F) Jurkat-
             TAg cells were transiently transfected with 2 µg of reporter plasmid, SRα-
             SEAP, along with indicated amount of expression plasmid, pSH1, containing
             F$_v$/caspase fusion proteins or control F$_v$s. After 24 hours cells were treated with
             half-log dilutions of AP1903 (or FK1012) and incubated for an additional 20
             hours before extracts were assayed for SEAP activity. (A) Dimerization is
10   sufficient for caspase-3 activation. Cells received 4 µg S-Casp3 (▲), S-F$_v$1-
             Casp3 (□), S-F$_v$2-Casp3 (■), or S-F$_v$3-Casp3 (Δ). (B) Caspase-3 activation is
             not sterically hindered by amino terminal FKBP12. Cells received 4 µg S-F$_v$1-
             F$_{vls}$1 (●), S-F$_v$1-F$_{vls}$1-Casp3 (O), S-F$_{vls}$2-Casp3 (▲), S-F$_v$1-Casp3 (□), S-F$_v$2-
             Casp3 (■), or S-F$_{vls}$1-Casp3 (Δ). (C) Caspase-1 activation is sterically
15   hindered by amino terminal FKBP12. Cells received 4 µg S-F$_v$2-Casp3
             (+AP1903 (□)), (+FK1012 (■)), S-F$_v$2-Casp1 (+AP1903(Δ), (+FK1012 (▲)),
             or S-F$_v$1-F$_{vls}$1 (+AP1903 (●)). (D) A flexible linker confers AP1903-sensitivity
             to caspase 1. Cells received 2 µg (□), 1 µg (■), or 0.5 µg (Δ) S-F$_v$1-F$_{vls}$1-
             Casp1, or 4 µg control plasmid, S-F$_v$1-F$_{vls}$1 (▲). (E) A flexible linker confers
20   AP1903-sensitivity to caspase 8. Cells received 4 µg (□), 2 µg (■), or 1 µg
             (Δ) S-F$_v$1-F$_{vls}$1-Casp8, or 4 µg control plasmid, S-F$_v$1-F$_{vls}$1 (▲). (F) A single
             short G-S linker augments the AP1903-sensitivity of caspase 1. Cells received
             1 µg S-F$_v$1-F$_{vls}$1-Casp-1 (Δ), S-F$_{vls}$1-Casp1 (□), S-F$_{vls}$2-Casp1 (■), or 4 µg S-
             F$_v$1-F$_{vls}$1 (▲). Inset (A and B) Equal aliquots of cell extracts were analyzed by
25   western blot with MoAb to the HA epitope ("E" figure 24B).

Figure 25.   Crosslinking the death effector domain of FADD is sufficient for triggering
             apoptosis with reduced basal toxicity relative to Fas, caspase 1 and 8. (A-D)
             As above, Jurkat-TAg cells were transfected with 2 µg SRα-SEAP plus the
             indicated expression plasmids. (A) FADD$_{100}$ is sufficient for FK1012-mediated

14

cytotoxicity. Cells received 4 µg S-F$_{pk}$3-FADD$_{125}$ (□), S-F$_{pk}$3-FADD$_{80}$ (Δ), S-

F$_{pk}$3-FADD$_{100}$ (■), or S-F$_{pk}$3-Δ25FADD$_{125}$ (▲). Inset (A) Equal aliquots of

cell extracts were analyzed by western blot as above. (B) Cells received 4 µg

S-F$_{pk}$3 (□), S-F$_{pk}$3-FADD$_{125}$V82 (▲), or S-F$_{pk}$3-FADD$_{125}$ (■). (C) Fas,

5   caspase 1, and caspase 8 have high basal activity relative to FADD$_{125}$ and

caspase 3. (D) Caspase 1 is the most AP1903-sensitive ADS developed). (C

and D) Cells received 2 µg S-F$_v$1-F$_{vis}$1 (□), S-F$_v$2-Fas (■), S-F$_v$1-F$_{vis}$1-

FADD$_{125}$ (Δ), S-F$_v$1-F$_{vis}$1-Casp8 (▲), S-F$_v$1-F$_{vis}$1-Casp1 (O), or S-F$_v$1-F$_{vis}$1-

Casp3 (●).

10   Figure 26.   Plasma membrane targeting of caspase-3 increases its AP1903 sensitivity and

basal activity. (A-B) Transient transfection assay was performed as above. (A)

Cells received 2 µg SRα-SEAP plus 4 µg N2-F$_v$2-Casp3 (□), Mas70$_{34}$-F$_v$2-

Casp3 (■), or S-F$_v$2-Casp3 (Δ), or 1 µg M-F$_v$2-Casp3 (▲). (B) Cells received

2 µg SRα-SEAP plus 4 µg (□), 1 µg (■), or 0.25 µg (Δ) M-F$_v$2-Casp3, or 4

15   µg S-F$_v$2-Casp3 (▲), or 4 µg control plasmid, S-F$_v$1-F$_{vis}$1 (O). (C-J)

Localization of caspase-3 to different intracellular membranes. HeLa cells

transiently transfected with cytoplasmic S-F$_v$2-Casp3-E (C), plasma membrane-

localized M-F$_v$2-Casp3-E (D), mitochondria-localized Mas70$_{34}$-F$_v$2-Casp3-E

(E), or nuclear N2-F$_v$2-Casp3-E (F) were fixed, stained with anti-HA

20   antibodies and examined by confocal microscopy. Alternatively, control

proteins were localized, including S-F$_v$2-E (G), M-F$_v$2-E (H), Bcl-x$_L$-E (I), or

Gal4-VP16-E (J). In each case, cells shown are representative of several

transfected cells.

Figure 27.   Nuclear-targeted caspase-1, -3, and -8 trigger apoptosis. (A-B) Transient

25   transfection assay was performed as above. (A and B) Cells received 2 µg

SRα-SEAP plus 2 µg nuclear targeted caspases, including N2-F$_v$1-F$_{vis}$1-Casp1

(Δ), N2-F$_v$1-F$_{vis}$1-Casp3 (▲), N2-F$_v$1-F$_{vis}$1-Casp8 (■), or control construct

N2-F$_v$1-F$_{vis}$1 (□). (C) Nuclear targeted caspase-3 functions efficiently. Cells

received SRα-SEAP plus 4 µg (□) or 1 µg (Δ) S-F$_v$2-Casp3, 4 µg (■) or 1 µg

(▲) N2-F$_v$2-Casp, or 1 µg S-F$_v$1-F$_{vls}$1 (○). (D) Nuclear targeted FADD$_{125}$ has reduced activity. Cells received reporter plasmid plus 2 µg S-F$_v$1-F$_{vls}$1-FADD$_{125}$ (■),N2-F$_v$1-F$_{vls}$1-FADD$_{125}$ (□), or N2-F$_v$1-F$_{vls}$1 (Δ).

16

Figure 46.   Outline and Western Blot showing expression and activation of ICE and
              YAMA;

Figure 47.   A) untreated JD-2a cell culture; B) control culture incubated with Adv-Fv1-
              YAMA expressing green fluorescent protein; C) cell culture incubated with
              virus and maintained in 50nM AP1903;

Figure 48.   Plated PC-3 cells incubated with ADV-FKBP/ICE and treated (+) or untreated
              with AP1903 at increasing MOI;.

Figure 49.   Plated JD-2a BPH cells incubated with ADV-FKBP/ICE and treated (+) or
              untreated with AP1903 at increasing MOI;

Figure 50.   Diagram illustrating protocol for treatment of s.c. prostate adenocarcinoma in
              situ with CID inducible caspases;

Figure 51.   Results of treatment of s.c. prostate adenocarcinoma with ADV-FKBP/ICE;

Figure 52.   Results of treatment of s.c. prostate adenocarcinoma with ADV-FKBP/ICE
              followed by administration of CID.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The strategy employed in this study to develop sensitive, conditional cytotoxic
molecules relies on chemically-induced dimerization (CID) (15-17), and the discovery that
full-length apoptosis signal transducing molecules, such as caspase zymogens, can undergo
inter-molecular processing to become fully active (reviewed in 20).

A chemical inducer of dimerization (CID) is defined as a dimer of the ligand for a
CID-binding domain (CBD). Responsiveness to CIDs is achieved by fusing CBDs to target
proteins. In this manner, CID administration leads to protein crosslinking. The CIDs used in
this study include the previously described, non-immunosuppressive FK506 dimer, FK1012,
and a novel fully synthetic FK1012 analog, AP1903, that is analogous to FK1012 acetylated
at the C_9 position of the FK506 moieties (Figure 18). This modification of FK506 prevents
binding of AP1903 to the highly-expressed endogenous FKBPs (K_m FKBP12 $\approx$ 250 Nm), but
leads to sub-nanomolar affinity to a mutant FKBP12 (F36V, abbr. F_v) (M. Gilman, personal

17

communication). The valine substitution of F_v creates a deeper drug-binding pocket, which accommodates the acetyl groups of AP1903.

Specific examples of conditionally lethal molecules comprising a chemical inducer binding domain fused to an apoptosis signal transducing factor described herein are

5   conditional alleles of the zymogens caspase-1 and caspase-3. The CID-binding domain (CBD), FKBP12, has been placed at the amino terminus of these proteins adjacent to the pro-domains of the inactive proteases. Upon administration of a lipid-permeable dimerizing drug, aggregation of apoptosis signal transducing factors, in this case caspases, occurs, leading to auto-proteolysis and activation. Further, it is demonstrated that this chemical activation of

10   either caspase-1 or caspase-3 is sufficient to trigger apoptosis in target cells. This technique is termed chemically-induced apoptosis (CIA) and the recombinant molecules are termed artificial death switches (ADS) or chemically inducible apoptosis factors.

Although conditional caspase-1 alleles are somewhat autotoxic, like previously described conditional Fas alleles (5), the conditional caspase-3 alleles appear to be completely

15   non-toxic in the absence of CID, even at high levels of expression. Interestingly, a truncated caspase-3 lacking its pro-domain is somewhat autotoxic, consistent with other reports that the pro-domains of caspases contribute to maintaining their quiescence in unstimulated cells (16). Further, the conditional caspase-1 allele appears to be completely insensitive to excess Bcl-x_L while the conditional caspase-3 allele can be blocked by an excess of Bcl-x_L levels. Finally,

20   both conditional caspase-1 and caspase-3 alleles can trigger apoptosis in a broad range of tissues. These results confirm that crosslinking caspases can lead to their activation in intact cells and demonstrate an expanded repertoire of proteins that can be activated by CID.

The pro-apoptotic conditional alleles were designed based on currently accepted models of Fas signaling (Fig. 1). In the design of conditional Fas (Fig. 2), FKBP12 (or

25   mutants) replaces the extracellular domain of Fas, and the myristoylation-targeting domain (M) of c-Src (residues 1-14) directs membrane localization (5). For conditional caspases (Figs. 3 and 23), CBDs are attached to their pro-domains. Following CID, pro-domains should be cleaved and the resulting, fully active proteases should be indistinguishable from

wild-type proteins. All constructs use in connection with Examples 2 through 8 follow the cassette cloning strategy outlined in Figure 4.

Caspase activation is a common integration point for diverse apoptotic stimuli and is therefore a logical control point for CIA. Given the examples of the instant invention, it will
5   be possible to use other factors involved in the signal transduction of apoptotic stimuli as chemically inducible apoptosis factors. Chimeric molecules containing a chemically inducible dimerization domain fused to the precursor form of the signal transducing molecule can be readily constructed by those of skill in the art. The present invention envisions the use of such molecules in a fashion entirely analogous to the caspase examples set forth below.

10   Examples of suitable apoptotic stimuli transducing molecules include, but are not limited to, receptors such as: the tumor necrosis factor family receptors, such as TNFRI (p55) and TNFRII (receptor 2, p75); DR3; DR4 (TRAIL-R1); DR5 (TRAIL-R2); TRAIL-R3; CD30; CD27; and p75NTR (neurotrophin receptor). Other suitable molecules include adapter molecules such as FADD, TRADD, RAIDD, Casper, SIVA, DAXX, MADD and the like.

15   Additional molecules that may be used to practice the present invention include all other members of the caspase family and apoptosis related serine/threonine kinases such as JNK1,2,3 and $p38_{\alpha,\beta,\gamma}$. Another class of molecules that may be used to practice the present invention are Bcl-2 family members that trigger apoptosis such as: Bax; Bak; BAD; Bcl-x_s; BIK, HRK, Bid, Bim and the like. Constructs comprising proteases, such as calpain, and

20   constructs comprising sphingomyelinases, neutral and acid, may also be used to practice the present invention.

EXAMPLE 1

General experimental methods for Examples 2-8.

Plasmid construction. To make M-F_{pk}2, F_{pk}3, and F_v2, F_{pk} (hFKBP12 (P89,K90))
25   and F_v (HFKBP12(V36)) were amplified by *Pfu*I PCR using primers: 5'-GCGACA CTCGAG GGA GTG CAG GTG GAA ACC-3' (SEQ ID NO:1) and 5'-CGACA GTCGAC TTC CAG TTT TAG AAG C-3' (SEQ ID NO:2) and the F_{pk} template, HFKBP(P89,K90) (17) or the F_v template, M46. The resulting products (and all other PCR fragments) were blunt-end ligated

into *EcoR*V-digested Pbluescript (Stratagene) to create PKS/F$_{pk}$ and PKS/F$_v$ and sequenced. The 330 bp *Xho*1/*Sal*1 fragments from PKS/F$_{pk}$ and PKS/F$_v$ were ligated in tandem into *Xho*1/*Sal*1-digested MF3E and SF1E (described previously in 18) to make F$_{pk}$3-E (three copies of F$_{pk}$), M-F$_{pk}$2-E (two copies F$_{pk}$) and F$_v$2-E (two copies F$_v$). An additional 5'-epitope

5   (E) was added to F$_{pk}$3-E to produce E-F$_{pk}$3-E by cloning hybridized oligonucleotides 5'-TCGAC TAT CCG TAC <u>GAC GTC</u> CCA GAC TAC GCA C-3' (SEQ ID NO:3) and 5'-TCGAG TGC GTA GTC TGG <u>GAC GTC</u> GTA CGG ATA G-3' (SEQ ID NO:4) into the 5' *Xho*I site. M-F$_{pk}$2-Fas was constructed by subcloning the *Xho*1/*Sal*1 Fas fragment from PKS/Fas (described previously 5) into *Sal*1-digested M-F$_{pk}$2-E vector. Caspase-1, caspase-3

10   and Δ20caspase-3 inserts were PCR amplified from plasmids pCDNA3/hICE/AU1 and PCDNA3/YAMA using the following primers containing *Xho*1 sites (5') and *Sal*1 sites (3'): HICE5X, 5'-CCGACA CTCGAG GCC GAC AAG GTC CTG AAG GAG-3' (SEQ ID NO:5); HICE3'S, 5'-CGTAGA GTCGAC GTC CTG GGA AGA GGT AGA AAC-3' (SEQ ID NO:6); YAMA5X, 5'-CCGACA CTCGAG GAG AAC ACT GAA AAC TCA GTG-3'

15   (SEQ ID NO:7); YAMA3S, 5'-CGTAGA GTCGAC GTG ATA AAA ATA GAG TTC TTT TGT-3' (SEQ ID NO:8); 20Yam5x, 5'-ACA CTCGAG ATA CAT GGA AGC GAA TCA ATG G-3' (SEQ ID NO:9). PCR products were subcloned into Pbluescript to create pKS/ICE, pKS/YAMA and pKS/20YAMA. *Xho*1/*Sal*1 fragments from these plasmids were then ligated into *Sal*1-digested E-F$_{pk}$3-E (abr. F$_{pk}$3) and F$_v$2-E vectors, to produce F$_{pk}$3-casp-

20   1, F$_v$2-casp-3, F$_{pk}$3-casp-3, and F$_{pk}$3-20casp-3. To make casp-3/S163, the 340 bp *Stu*I-*Sal*II fragment of pKS/YAMA was reamplified using primers 5'-ATT C<u>AG GCC TCC</u> CGT <u>GGT ACC</u> GAA CTG GAC TGT GGC ATT GAG-3' (SEQ ID NO:10) and YAMA3S, subcloned into pBluescript to make pKS/YAMAS and sequenced. The mutant *Stu*I-*Sal*II fragment was substituted with the wild-type fragment in pKS/YAMA to make pKS/YAMA/S136 and

25   ultimately F$_{pk}$3-casp-3/S136 and F$_v$2-casp-3/S136. The SRα-SEAP reporter plasmid was created by cloning the secreted alkaline phosphatase (SEAP) cDNA from NFAT-SX into the polylinker of pBJ5 (13). Bcl-x$_L$ was amplified from a Bcl-x$_L$ cDNA using primers 5'-CCGACA <u>CTCGAG</u> TCT CAG AGC AAC CGG GAG CTG G-3' (SEQ ID NO:11) and 5'-CGTAGA <u>GTCGAC</u> TTT CCG ACT GAA GAG TGA GCC CA-3' (SEQ ID NO:12) and

20

subcloned into *XhoI/SaI*I-digested F1-E. All plasmids were prepared by two rounds of CsCl centrifugation. Underlined = restriction sites.

Tissue Culture. Jurkat-TAg cells (19) were grown in RPMI 1640 medium, 10% Fetal Bovine Serum (FBS), 10 mM Hepes (pH 7.4), 100 units/ml penicillin, and 100 µg/ml streptomycin. HeLa and 293 cells were grown in Dulbeccos Modified Eagle Medium, 10% FBS and antibiotics.

SEAP Assays. Jurkat TAg cells (10^7) in log phase growth were electroporated (950 µF, 250V; Gene Pulser *II*) with expression plasmid and 1-2 µg SRα-SEAP. After 24 hours, transformed cells were stimulated with CID or anti-Fas antibody (CH.11, Kamiya Biomedical). After an additional 20 hours, supernatants were assayed for SEAP activity as described previously (15). Units of SEAP activity are reported directly and as a percentage of activity relative to no stimulation within the same transfections (% Relative Activity).

Western Blot Analysis.   Jurkat TAg cells were electroporated with 2 µg of plasmid, cultured 36 hours, and stimulated with drug for the indicated time period. Approximately 5×10^5 cells were lysed in 100 µl RIPA buffer (0.01M TrisHCl pH 8.0, 140 mM NaCl, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 1% sodium deoxycholate, 0.1% SDS) on ice for 30 minutes. Cell debris were pelleted and supernatants were boiled in 1:1 Laemmli sample buffer (with 5% ß-ME) for 5 minutes. Equal volumes of extracts were separated on a 15% SDS-PAGE gel. Membranes were incubated with monoclonal anti-HA epitope antibody, HA.11 (BABCO) followed by polyclonal HRP-conjugated goat anti-mouse antibody (Bio-Rad). Bands were detected with SuperSignal- Chemiluminescent Substrate (Pierce).

Lipofection and Cell Selection. Jurkat TAg cells (4×10^6) were transfected with 12 µl DMRIE-C reagent (Gibco-BRL), 2 µg of green fluorescent protein (GFP) expression vector pEGFP (Clontech), 2 µg of the pMACS-H2-K^k vector (Miltenyi), and 2-4 µg of CID-responsive plasmids in OPTI-MEM I reduced serum media. Transfected cells were purified to approximately 60% by MACSelect magnetic bead selection on MiniMACS separation columns (Miltenyi) as assessed by FACS analysis (described below). Selected cells were resuspended in 2 ml Jurkat TAg media, split into two aliquots, and one was treated with drug.

21

Flow Cytometry. Cells were washed with PBS + 1% FBS, resuspended in staining

buffer (PBS, 1% FBS, 0.5 µg/ml Propidium Iodide (PI)) and analyzed within 1 hour. Two

color flow cytometry of PI (band pass=525) and GFP (band pass=620), was performed using

a Coulter Epics XL MCL cytometer. Greater than 20,000 events were counted per sample.

Gates were set using mock transfected cells, unstained cells transfected with GFP, and stained

nontransfected cells. Data is reported as the percent of PI^-/GFP^+ cells after drug addition

relative to untreated cells in triplicate cultures.

FuGENE™6 Transfection and Luciferase Assays. HeLa and 293 cells were plated

at $2x10^5$ cells/35 mm dish 18 hours before transfection. Plated cells were transfected with 2

µg of constitutive luciferase reporter pGL2-Control (Promega), 2 µg of test plasmid, and 6

µl FuGENE™6 (Boehringer-Mannheim) in OPTI-MEM I media. Jurkat TAg cells ($4x10^6$)

were transfected as described above with 2 µg of pGL2-Control, 2 µg of test plasmid, and 12

µl of DMRIE-C in OPTI-MEM I media. After 24 hours, cells were split into two groups and

one was treated with 500 nM AP1903 (F_v constructs) or FK1012 (F_{pk}). After an additional

24 hours, cells were lysed in 100 µl of Reporter Lysis Buffer (Promega) with three

freeze/thaw cycles and 10µl of the supernatants (or constant dilutions) were assayed with 90

µl of Luciferase Assay Substrate (Promega) using a Turner TD-20e luminometer. Data is

reported as the % of luciferase activity after drug addition relative to luciferase activity

without drug in duplicate cultures. All transfections were performed at least three times and

averaged.

EXAMPLE 2

Crosslinking caspase-1 triggers apoptosis in mammalian cells.

Two critical factors that are required for a broadly applicable ADS are high sensitivity

to drug and low basal toxicity. In previously reported experiments, it was demonstrated that a

Fas-based ADS could trigger apoptosis in mammalian cells following FK1012 administration

(5). However, overexpression of this Fas allele was somewhat autotoxic, consistent with

reports that the cytoplasmic domain (DD) of Fas can spontaneously multimerize when

expressed at high levels (21). The problem of autotoxicity was exacerbated by the relatively

22

high expression level of chimeric M-FKBP$_2$-Fas required to kill cells efficiently. The requirement for a high level of expression of the chimeric Fas molecules was likely a result of the fact that FK1012 binds equally well to endogenous and ectopic FKBPs thus, a high concentration of recombinant Fas molecules was required to compete with the endogenous

5   FKBPs.

An additional factor that may have contributed to the requirement for a high level of recombinant Fas expression to effect efficient cell killing is the presence of regulatory mechanisms designed to prevent the entry of the cell into apoptosis. Fas signaling does not always lead to apoptosis due to intracellular checkpoint genes, like Bcl-2 and Bcl-x$_L$ (34,35),

10   regulation of caspase-8 activation (22) or other mechanisms (23). Therefore, downstream effectors of apoptosis, such as caspase-1 or caspase-3 were constructed.

Jurkat TAg cells were cotransfected with reporter plasmid, SRα-SEAP, constitutively expressing secreted alkaline phosphatase, along with various amounts of a fusion construct in which caspase-1 is fused to 3 FKBP12s, F$_{pk}$3-casp-1, or a control plasmid expressing 3

15   FKBPs, F$_{pk}$3 (Figures 5 and 6). Jurkat TAg cells were transiently-transfected with: 4 µg F$_{pk}$3-casp-1 (open circles), 2 µg F$_{pk}$3-casp-1 (closed circles), 1 µg F$_{pk}$3-casp-1 (open triangles), 0.5 µg F$_{pk}$3-casp-1 (closed triangles), 0.25 µg F$_{pk}$3-casp-1 (open squares), or 4 µg F$_{pk}$3 (closed squares). After 20 hours, transfected cells were treated with FK1012. After an additional 24 hours, SEAP activity was assayed and reported directly (Figure 5) or as a percentage of

20   activity from untreated cells in identical aliquots from the same transfections (Figure 6). Data is representative of three independent experiments performed in duplicate. Apoptosis of cells is indicated by a net reduction in reporter activity.

The FKBP12 variant, F$_{pk}$ (P89,K90) binds FK1012 as well as wild-type FKBP12, but the two amino acid changes prevent CID-independent interactions with cellular proteins, like

25   calcineurin (17). This eliminates a mild toxicity associated with overexpressing wild-type FKBP12. Similar to M-FKBP$_3$-Fas, in the presence of FK1012, there is a dramatic reduction of reporter activity in cells expressing F$_{pk}$3-casp-1 that is not present in cells expressing control F$_{pk}$3 (Figures 5 and 6). Also like conditional Fas, caspase-1 is autotoxic as indicated by the CID-independent reduction in reporter activity in the cells transfected with F$_{pk}$3-casp-1

expressing plasmid (Figure 5, compare open circles to closed squares). However, this autotoxicity can be greatly reduced with only a marginal decrease in efficacy by transfecting less caspase-1 plasmid (Figures 5 and 6, open squares).

EXAMPLE 3

5   Conditional caspase-3 displays extremely low basal activity yet triggers apoptosis efficiently in the presence of CIDs.

In contrast to caspase-1 and Fas, conditional caspase-3 alleles are not apparently autotoxic (Figures 7-9). With reference to Figures 7 and 8, Jurkat TAg cells were transiently-transfected with: 2 μg F_v2-casp-3 (open squares), or 2 μg F_v2-casp-3/S163 (closed squares).

10   With reference to Figure 9, Jurkat TAg cells were transfected with: 2 μg $F_{pk}3$-casp-3/S163 (closed triangles), 2 μg $F_{pk}3$-casp-3 (open squares), or 2 μg $F_{pk}3$-Δ20casp-3 (closed squares). After 20 hours, transfected cells were treated and analyzed as before. Data is representative of at least three independent experiments performed in duplicate.

In the absence of the novel CID, AP1903, reporter activity is the same in cells

15   transfected with F_v2-casp-3, control F_v2 (not shown) or control F_v2-casp-3/S163, which is inactive due to the substitution of serine for cysteine within the conserved active site QACRG (SEQ ID NO:13) motif (Figures 7 and 8) (20). However, in the presence of AP1903 (EC_{50} ≈ 1 nM), crosslinking caspase-3 was sufficient to trigger a dramatic reduction in reporter activity of ≈65%, comparable to Fas or caspase-1 signaling (Figure 8). Enzymatically

20   inactive caspase-3, F_v2-casp-3/S163, could not reduce reporter activity even in the presence of 100 nM AP1903. The absence of toxicity of F_v2-casp-3 (and $F_{pk}3$-casp-3, Figure 9) suggests that caspase-3 is less likely than caspase-1 to be spontaneously activated in Jurkat cells. The increased specificity of AP1903 for F_v is reflected by an increased drug efficacy (compare Figures 7 and 9).

25   To test whether the pro-domain of caspase-3 contributes to low basal activity, 20 residues from the amino-terminus of caspase-3, comprising most of the pro-domain were removed. Interestingly, removal of the pro-domain makes caspase-3 somewhat autotoxic (Figure 9, closed squares), although CID induces a more complete diminution of reporter.

24

EXAMPLE 4

Administration of CID causes rapid processing of F$_v$2-caspase-3.

Processing of caspase-3, and other caspases, ordinarily involves two or more cleavages after aspartic acid residues. To confirm that the CID-mediated diminution of reporter activity was caused by activation of the conditional caspases, the processing and degradation of conditional caspase-3 was directly examined. Jurkat cells were transfected 2 μg F$_v$2-casp-3 or F$_v$2-casp-3/S163. After 36 hours, aliquots of cells were treated with 100 nM or 500 nM AP1903 for various times. Following these incubations, cell extracts were analyzed by western blotting using monoclonal antibodies to an epitope tag (HA) placed at both ends of the construct. The results are shown in Figure 10. When 500 nM AP1903 was administered, degradation of full-length caspase-3 was complete within 2 hours, while no decrease in control caspase-3/S163 was detectable. When cells were treated with 100 nM AP1903, full degradation of F$_v$2-casp-3 took four hours.

Figure 11 shows an anti-HA epitope immunoblot of extracts from Jurkat TAg cells transfected as in Figure 10 and treated for eight hours with half-log dilutions of AP1903 at the concentrations indicated. As little as 10 nM AP1903 was sufficient to cause the processing and degradation of the majority of F$_v$2-casp-3. The breakdown products of caspase-3 activation were not seen even though epitope tags were present at both ends of the protein. Similar results were seen with F$_{pk}$3-casp-1 (not shown) although a reduced amount of chimeric protein was seen, presumably due to autoprocessing of caspase-1. Therefore, homomultimerization of the caspases, caspase-1 and caspase-3, is sufficient for their activation.

EXAMPLE 5

Conditional caspase-1 and caspase-3 trigger apoptosis in the presence of excess Bcl-x$_L$.

To determine if conditional caspases can bypass inhibition by the checkpoint gene Bcl-x$_L$, conditional caspase-1 and caspase-3 alleles were coexpressed along with an excess of Bcl-x$_L$. A comparison was made between the extent of apoptosis induced by chemical inducer (Figures 12 and 13) and the extent of apoptosis induced by anti-Fas antibody (Figures 14 and

15). The results of the caspase-1 alleles are presented in Figures 12 and 14 while the results obtained with caspase-3 alleles are presented in Figures 13 and 15.

Jurkat TAg cells were transiently transfected with the following caspase-1 construct expressing plasmids: $F_{pk}3$-casp-1 (open triangles in Figure 12; 1 in Figure 14), $F_{pk}3$-casp-1 +

5   1 µg Bcl- x_L (closed triangles in Figure 12; 2 in Figure 14), + 2 µg Bcl-x_L (open squares in Figure 12; 3 in Figure 14), + 4 µg Bcl-x_L (closed squares in Figure 14; 4 in Figure 14), or $F_{pk}3$ + 4 µg Bcl-x_L (closed circles; 5 in Figure 14). Jurkat TAg cells were transiently transfected with the following caspase-3 construct expressing plasmids: F_v2-casp-3 (open triangles in Figure 13; 1 in Figure 15), F_v2-casp-3 +1 µg Bcl- x_L (closed triangles in Figure 13; 2 in Figure

10   15), + 2 µg Bcl- x_L (open squares in Figure 13; 3 in Figure 15), + 4 µg Bcl-x_L (closed squares in Figure 13; 4 in Figure 15), or F_v2-casp-3/S163 + 4 µg Bcl-x_L (closed circles in Figure 13; 5 in Figure 15). Cells were transfected and assayed as before. Data is representative of at least three independent experiments. Data is given relative to untreated cells from the same transfection.

15   Although ectopically-expressed Bcl-x_L inhibits Fas-mediated apoptosis by ≈50% in Jurkat cells (Figure 14 lanes 2-5), it consistently had no inhibitory effect on $F_{pk}3$-casp-1 mediated apoptosis (Figures 12 and 16), even when a large molar excess of Bcl-x_L was expressed (Figure 12). However, Bcl-x_L is able to block caspase-3 mediated signaling at a similar 4-fold molar excess (Figure 13, closed squares). Likewise, the presence of F_v2-casp-3

20   is able to reduce the inhibition of Fas signaling by Bcl-x_L by about 50% (Figure 15, lanes 2-4). Control F_v2-casp-3/S163 does not attenuate the protein function of Bcl-x_L, suggesting that a functional protease domain is necessary for the partial neutralization of Bcl-x_L (compare Figure 15, lanes 2-5).

EXAMPLE 6

25   Direct demonstration of apoptosis in Jurkat cells.

Since the above experiments are based on an indirect reporter assays for apoptosis and cannot definitively rule out that conditional molecules are reducing transcription, translation or protein stability of reporter, the efficacy of CIA was reexamined more directly. To enrich

for ADS-expressing Jurkat cells, cells receiving conditional alleles were cotransfected with a selectable surface marker, consisting of the extracellular domain of the murine MHC molecule, K^k, and GFP to mark transfected cells and the indicated plasmids. 24 hours later, cells were sorted using magnetic bead-conjugated K^k antibodies, leading to an enrichment of

5   60% GFP$^+$ cells from ≈15% unsorted. Sorted cells were split into two groups, one of which was treated with 500 nM AP1903 (F$_v$ chimeras) or FK1012 (F$_{pk}$ chimeras). After 24 hours, cells were stained with propidium iodide and analyzed by FACS to determine the percentage of viable GFP$^+$/PI$^-$cells. The % survival indicated is the percentage of viable cells after treatment with drug relative to the untreated aliquots. Also, in separate transfections, a 1:1

10   ratio of Bcl-x$_L$-containing plasmid to ADS-containing plasmid was added. Cells were analyzed by FACS to determine the percentage of GFP$^+$ cells that survived after treatment with drug. While Bcl-x$_L$ could inhibit endogenous Fas signaling by ≈50% (Figure 14), there was very little Bcl-x$_L$ effect on CID-mediated apoptosis by conditional caspase-1 or caspase-3 (Figure 16). This demonstrates that conditional caspases can bypass intracellular checkpoints,

15   including Bcl-x$_L$, and should therefore have broader usefulness than a Fas-based ADS.

EXAMPLE 7

Conditional Fas, caspase-1 and caspase-3 trigger apoptosis in a wide panel of cell lines.

To determine if the conditional caspase-1 and caspase-3 alleles functioned in a range of cells, CID-mediated apoptosis was examined in various cell lines and the results are

20   presented in Figure 17. Jurkat TAg, 293 and HeLa cells were transiently-transfected with a constitutively-expressing luciferase reporter plasmid and control vector MF$_v$2 (speckled), MF$_v$2-Fas plasmid (wide stripe), control vector F$_{pk}$3 (narrow stripe), F$_{pk}$3-casp-1 (bricks), or F$_v$2-casp-3 (solid). After 24 hours, transfected cells were split into duplicate cultures and 500 nM drug (AP1903 for F$_v$, FK1012 for F$_{pk}$) was added to one culture for an additional 24

25   hours. The % relative reporter activity is the percent of luciferase activity after drug addition relative to untreated cells. Error bars represent the standard deviation of the mean activity of three independent transfections. While conditional Fas did not trigger apoptosis in 293 cells, conditional caspase-1 and caspase-3 functioned in every cell tested. In addition to the cell

27

lines reported here, high efficiency of killing has been demonstrated in the prostate cancer cell lines RM-1, RM-9, AND TRAMP-C2. In view of the foregoing, the caspase-based ADSs may lead to a more universally-applicable death switch.

EXAMPLE 8

5   Conditional Fas and caspase-3 trigger apoptosis in smooth muscle cells derived from BPH.

Conditional Fas, YAMA and a YAMA construct containing a single, inactivating point mutation were cotransfected with a luciferase reporter plasmid (pGL2) into JD and CR-2a cell lines. These are smooth muscle cell lines derived from prostate tissue samples taken from patients with BPH. Cells were maintained in control media ± 100 µM AP1903 for 24 hours.

10   Cells were then lysed and assayed for luciferase activity as a marker of cell survival. The results obtained with CR-2a cells are presented in Figure 21 and the results with JD cells are presented in Figure 22.

There was no significant reduction in the percentage of surviving cells with or without AP1903 in cells transfected with conditional Fas or inactivated YAMA. In contrast, luciferase

15   activity in cells transfected with conditional YAMA and treated with AP1903 fell from 668±67 to 119±13 representing an 82% reduction in reporter activity. This demonstrates the efficacy of the present invention in cell types found in BPH. It is worth noting that a conditional Fas-based treatment for BPH is not possible since the Fas construct was not effective in causing apoptosis in BPH derived cell lines. It is quite likely that Fas-based

20   methods will be ineffective in many other cell types, thus severely limiting the utility of this approach.

Since different tissues or tumor lines are likely to be inhibited by one or more anti-apoptosis "gatekeeper" proteins, such as c-FLIP, Bcl-x_L, or IAPs, a broad repertoire of conditional pro-apoptotic proteins is likely to be useful to find the ADS(s) that work best for

25   every cell type. By using the high-specificity CID, AP1903, and its cognate binding domain, Fv, we have developed a panel of highly sensitive ADSs based on Fas and the Fas signaling

intermediates FADD, caspase-1, 3, and 8.   Further, we have investigated several parameters

relevant to caspase activation, (i) extent of crosslinking, (ii) interdomain flexibility, and (iii)

intracellular localization. These improved ADSs now meet many, if not all, of the desiderata

for a broadly applicable suicide switch: (a) They trigger apoptosis within hours of activation,

5   (b) function independently of the cell cycle, (c) have low basal activity when expressed at

minimal functional levels, (d) are based on endogenous proteins, and (e) can trigger apoptosis

in multiple tissues independently if different CID/CBD combinations are used (Spencer et al.,

1993;Belshaw et al., 1996). This data demonstrates that virtually all Fas signaling

intermediates can be regulated by CIDs. The exquisitely sensitive AP1903-responsive Fas

10   signaling intermediates described here should be able to function as suicide switches not only

for gene therapy vectors but also for a variety of animal models based on temporally regulated

and tissue-specific cell ablation.

EXAMPLE 9

General experimental methods for Examples 10-15.

15   **Plasmid construction.** All constructs were assembled from Pful amplified fragments

typically flanked by a 5' XhoI and 3' SalI site. PCR products were initially subcloned into

pCR(r)-Blunt (Invitrogen) and sequenced. All expression plasmids were prepared by two-spin

CsCl centrifugation and checked for expression by western blot. Parent expression plasmid

pSH1/S-$F_{pk}3$-E, containing 3 tandem copies of ~330 bp $hFKBP12_{P89, K90}$ and a 3' hemaglutinin

20   epitope (E) cloned into expression vector pSH1 (a high copy version of pBJ5), was described

previously (MacCorkle et al., 1998). Inserts $S-F_v1-E$, $S-F_v2-E$, and S-Fv3-E were made by

substituting $F_{pk}3$ with one to three tandem F_vs $hFKBP12_{v36}$ previously described (Clackson et

al., 1998;MacCorkle et al., 1998). In $S-F_{vis}1-E$ and $S-F_{vis}2-E$, $F_{pk}3$ is replaced with one or two

copies of "short" linkered F_v ("F_{vis}"). F_{vis} was amplified from F_v using primers hFK5X: 5'-

25   gcgacactcgag ggagtgcaggtggaaacc-3' and hFKL3S1: 5'-acagtcgac

tccggatccaccgccagattccagttttagaagctccac-3'. In $S-F_v1-F_{vis}-E$, F_{vis} is subcloned into the 3' SalI

site of $S-F_v1-E$. To make $N2-F_v2-E$ (and other variations), oligonucleotides 5'-tcgac

cctaagaagaagagaaaggta c-3' and 5'-tcgag tacctttctcttcttcttagg g-3', containing the nuclear

localization sequence, PKKKRKV, from SV40 large T antigen (Boulikas 1993), were

annealed and subcloned in tandem into the 5' XhoI site of S-F$_v$2-E. To make Mas70$_{34}$-F$_v$2-E,

the mitochondria-targeting sequence from pMas70 (residues 1-34) (Hase et al., 1984) was

PCR amplified from M-Raf (Wang et al., 1996) using primers 5SCMAS70: 5'-

5   cgaca<u>ccgcgg</u>ccacc atgaagagcttcattacaaggaac-3' and 3XMAS70P: 5'-aca<u>ctcgag</u>

ttgttgcaattggttgtaataatagtaggcaccgatggc-3'. The resulting ~120 bp SacII/XhoI fragment

(Mas70$_{34}$) was subcloned into SacII/XhoI-digested S-F$_v$2-E. M-F$_v$2-E and M-F$_v$2-FAS-E

were described previously (MacCorkle et al., 1998).

Human caspase 1 (Casp1), 3 (Casp3), and 8 (Casp8) inserts were PCR amplified from

10   plasmids pcDNA3/hICE-AUI, pcDNA3/YAMA, and pcDNA3/FLICE, respectively, using

primers, hICE5X: 5'-ccgaca<u>ctcgag</u> gccgacaaggtcctgaaggag-3' and hICE3ST: 5'-agagtcgac

ttaatgtcctgggaagaggtagaaac-3'; YAMA5X: 5'-ccgaca<u>ctcgag</u> gagaacactgaaaactcagtg-3' and

YAMA3S: 5'-cgtagagtcgac gtgataaaaatagagttctttgt-3'; and FLICE5S: 5'-agagtcgac

atggacttcagcagaaatctttatg-3' and FLICE3S: 5'-cgtaga<u>gtcgac</u> atcagaagggaagacaagttttttc-3'.

15   Resulting XhoI/SalI (caspase 1,3) or SalI (caspase 8) fragments were

subcloned into the SalI sites of the appropriate vectors. Human FADD$_{125}$ and FADD$_{100}$ were

PCR amplified from plasmid, pcDNA3/AU1-FADD, using 5' primer FADD5X: 5'-

ccgaca<u>ctcgag</u> gacccgttcctggtgctgc-3' and 3' primer FADΔDD3X: 5'-

ccgacactcgagcttggtgtctgagactttgagc-3' or FADΔC3X: 5'-aca<u>ctcgag</u> tgctgcacacaggtcttcttccc-

20   3', respectively. FADD$_{80}$ is from the ~240 bp XhoI/SalI fragment of FADD$_{125}$. Human

$_{25}$FADD$_{125}$ was amplified using primers Δ25Fad5x: 5'-aca<u>ctcgag</u> ctatgcctcgggcgcgtgggc-3' and

FADD5X. To make S-F$_{pk}$3-FADD$_{125}$V82, residues 81 to 125 of FADD$_{125}$ were reamplified

using primers 5SFADV82: 5'-cgc<u>gtcgac</u> gacgtcgaggcgggggcggcgg-3' and FADΔDD3X. The

resulting ~140 bp SalI/XhoI fragment was then subcloned into the SalI site of pSH1/S-F$_{pk}$3-

25   FADD$_{80}$-E. Reporter plasmid SRα-SEAP was described previously (MacCorkle et al., 1998).

Cloning sites are underlined and codons are separated.

Tissue Culture. Jurkat-TAg cells were grown in RPMI 1640 medium, 10% Fetal

Bovine Serum (FBS), 10 mM Hepes (pH 7.4), 100 units/ml penicillin, and100 (g/ml

30

streptomycin. HeLa cells were grown in Dulbecco's Modified Eagle Medium, 10% FBS and penicillin/streptomycin.

SEAP Assays. Jurkat TAg cells (10^7) in log phase growth were electroporated (950 μF, 250 V) with expression plasmid and 2 μg SRa-SEAP. After 24 hours, transformed cells

5   were stimulated with CID. After an additional 20 hours, supernatants were assayed for SEAP activity as described previously (Spencer et al., 1993). Units of SEAP activity are reported directly and as a percentage of activity relative to no stimulation ("% Relative SEAP activity"). All experiments were repeated at least three times and representative experiments performed with duplicate samples are shown.

10   **Western Blot Analysis.** Approximately 106 Jurkat TAg cells were lysed in 20 μl RIPA buffer (0.01M TrisHCl pH 8.0, 140 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1:100 Protease Inhibitor Cocktail (Sigma P2714)) on ice for 20 minutes. Cell debris were pelleted and supernatants were boiled in 1:1 sample buffer (5% beta-mercaptoethanol in Bio-Rad Laemmli buffer) for 3-5 minutes. Alternatively, cells were

15   lysed directly in 2X Laemmli buffer to detect nuclear proteins. Equal volumes of extracts were separated on a 15 % SDS-PAGE gel. Membranes were blotted with anti-HA antibody, HA.11 (BABCO) and then with polyclonal HRP-conjugated goat anti-mouse antibody. Bands were detected with SuperSignal® chemiluminescent substrate (Pierce).

Immunofluorescent Staining Protocol. HeLa cells were plated at 2 x 10^5 cells per

20   10-cm dish the night before transfection. Plated cells were incubated with 2 μg of indicated expression plasmids, containing various HA-tagged fusion proteins, resuspended in 3 μl FuGENE™6 (Boehringer-Mannheim) in OPTI-MEM® I media (Gibco-BRL). On day two, transfected cells were transferred to staining slides @ 10^4 cells per spot and incubated overnight @37°C. Adhered cells were fixed in 4% paraformaldehyde (10'), permeabilized in

25   minus 20°C methanol (2'), rinsed 3 x in PBS, and incubated for 1 hr @ RT with HA.11 diluted 100X in PBS/3% serum. Following 3 PBS rinses, cells were incubated with FITC-conjugated goat anti-mouse polyclonal Ig (Pharmingen) in PBS/3% serum for 45' in the dark at RT. Following 3 x 10' PBS rinsing, cells were treated with Vecta-shield anti-bleach mounting

31

medium (Vector Laboratories, Burlingame, CA) and stored in darkness at 4°C until analysis using a Multiprobe 2001 confocal system using Image Space software (Molecular Dynamics).

EXAMPLE 10

Dimerization is sufficient for caspase 3 activation.

5   Following administration of CIDs, caspases containing amino terminal CBDs should be crosslinked, leading to intermolecular processing in some cases (Fig. 23A). Since pro-domains with attached CBDs are removed, CID-activated proteins should be indistinguishable from physiologically activated caspases.

              To determine the number of FKBPs that are needed for optimal CID-mediated caspase

10   activation, we attached 0, 1, 2, or 3 copies of $FKBP12_{v36}$ (abbreviated "F_v") to the amino terminus of caspase-3 (Fig. 23B). Since AP1903 binds with high affinity to Fv ($K_d \sim 0.1$ nM) (Clackson et al., 1998) but with low affinity to wild-type FKBP12 ($K_d = 67$ nM), high specificity for F_V is achieved. Individual constructs were transiently transfected into Jurkat TAg cells along with the reporter plasmid, SRα-SEAP, containing secreted alkaline

15   phosphatase (SEAP) under the transcriptional control of the constitutively active promoter, SRα. Twenty-four hours later, cell aliquots were treated with increasing amounts of AP1903. After an additional twenty hours, cell supernatants were assayed for reporter activity. Although all constructs were expressed at comparable levels (Fig. 24A), constructs containing either one or two F_Vs were equally sensitive to AP1903 as reflected by the dramatic decrease

20   in SEAP activity ($IC_{50} \sim 3$ nM), whereas constructs containing three F_vs were much less sensitive ($IC_{50} \sim 150$ nM) to AP1903. S-F_v3-Casp3 is however still sensitive to the larger (i.e. MW ~1800 D) CID, FK1012 ($IC_{50} \sim 20$ nM; data not shown). Reductions in reporter activity by this assay faithfully reflect apoptosis as determined by flow cytometry ((MacCorkle et al., 1998) and data not shown). These results demonstrate that dimerization of caspase-3 is

25   sufficient for its activation while excess crosslinking by the relatively small CID, AP1903 (MW ~1200 D), may "lock" caspases into inactivatable conformations.

32

EXAMPLE 11

Caspase-3 activation is not sterically hindered by amino terminal FKBP12.

Two possible, non-exclusive, models can account for CID-mediated caspase activation: (i) CIDs increase the proximity of procaspases, increasing the likelihood that trans-proteolysis will occur and (ii) CIDs actively maintain the correct orientation for caspase processing. If model (i) is correct, then molecules should be relatively insensitive to orientation and spacing between FKBPs and caspases. If model (ii) is correct, then the converse is true. To test these two possibilities, we engineered a small, six amino acid G-S-G-G-G-S linker/spacer between F_v and caspase-3 permitting increased flexibility (Fig 23B). Again, constructs were transiently transfected into Jurkat TAg cells and treated after 24 hours with AP1903. We observed no significant difference in the dose response to AP1903 between constructs with or without the small linker, regardless of whether one or two F_vs were fused to caspase-3 (compare S-F_v1-Casp3 with S-F_{vls}1-Casp3 and S-F_v2-Casp3 with S-F_v1-F_{vls}1-Casp3; Fig. 24B). In contrast, construct S-F_{vls}2-Casp3, containing 2 linkered FKBPs ("F_{vls}") was less sensitive to AP1903, presumably because the increased rotational freedom of this construct reduces the probability that the correct conformation for cleavage occurs. These results support the model that the orientation by which caspases are brought together is important for their activation, and that AP1903 fortuitously crosslinks S-F_v1-Casp3 in an appropriate orientation that is not improved, and may be decreased, by increasing the flexibility and rotational freedom of the crosslinked molecules.

EXAMPLE 12

The activation of caspase-1 and -8 by AP1903 is sterically hindered by amino terminal FKBP12.

While F_v2-Casp3 does not require a flexible linker for efficient activation by AP1903, caspases-1 and -8 fused to two Fvs, S-F_v2-Casp1 and S-F_v2-Casp8, cannot be activated efficiently by AP1903 (IC_{50} caspase 1 ~ 200 nM; Fig. 24C and data not shown). However, the larger CID, FK1012, can activate S-F_v2-Casp1 (IC_{50} ~ 1 nM), despite the lower affinity (by ~ ten-fold) of FK1012 for F_v versus AP1903 and that FK1012 does not discriminate

against endogenous FKBPs. In contrast, the advantages of AP1903 versus FK1012 are readily apparent on the activation of S-F$_v$2-Casp3. These results imply that either AP1903 brings S-F$_v$2-Casp1 and F$_v$2-Casp8 into unfavorable orientations for processing or that steric hindrance prevents the efficient crosslinking of these FKBP/caspase

5   chimeras.

Therefore, to increase AP1903 sensitivity, we fused caspase-1 and 8 to the linkered FKBP, F$_{vls}$, as above. As hypothesized, the use of a flexible linker in S-Fv1-F$_{vls}$1-Casp1 (Fig. 24D) and in S-Fv1-F$_{vls}$1-Casp8 (Fig. 24E) led to alleles of caspase-1 and -8 that were exquisitely sensitive to AP1903 (IC$_{50}$ caspase-1 ≤ 100 pM; IC$_{50}$ caspase-8 ~ 100 pM). Again,

10   providing too much flexibility, as in S-F$_{vls}$2-Casp1, reduced the responsiveness to AP1903 (Fig. 24F), and adding the longer linker, G-G-S-G-G-G-S-G-G-G, almost completely abrogated AP1903 responsiveness (data not shown). In each case, however, the basal drug-independent cytotoxicities of linkered caspase-1 and -8 constructs were the same as unlinkered constructs, implying that amino terminal Fvs do not sterically hinder stochastic

15   caspase interactions. Nevertheless, since S-F$_v$1-F$_{vls}$1-Casp1 and -Casp8 are highly sensitive to AP1903, reducing protein expression to levels that are still sensitive to AP1903 (Figs. 24D and 24E) can largely eliminate these basal toxicities.

EXAMPLE 13

Crosslinking the death effector domain of FADD is sufficient for triggering apoptosis with

20   reduced basal toxicity.

Since caspases, such as caspase-1 and 8, can have high basal activity when overexpressed and Fas is autotoxic due to the tendency of death domains to self-associate (Boldin et al., 1995), we investigated whether CID-mediated crosslinking of the adapter molecule FADD could trigger apoptosis with lower basal activity. Therefore, we fused the

25   amino terminus of FADD (FADD125; residues 1-125), containing the DED, to a trimer of FKBP12$_{P89, K90}$ to get S-F$_{pk}$3-FADD$_{125}$. As above, we cotransfected reporter plasmid into Jurkat TAg cells along with S-F$_{pk}$3-FADD$_{125}$ or variants, including S-F$_{pk}$3-Δ25FADD$_{125}$ (residues 26-125), S-F$_{pk}$3-FADD$_{100}$ (residues 1-100), or S-F$_{pk}$3-FADD$_{80}$ (residues 1-80). While

34

crosslinking FADD125 and $FADD_{100}$ led to FK1012-dependent diminution of reporter activity, further truncation of FADD, as in $\Delta 25FADD_{125}$ and $FADD_{80}$, eliminated FK1012-dependent toxicity (Fig. 25A). The lower stability of these truncated proteins may contribute only partially to this lack of activity (Fig. 25A, inset) since $S-F_{pk}3-FADD_{125}$ and $-FADD_{100}$ still

5   function better than $S-F_{pk}3-FADD_{80}$ even after normalizing transfections for steady-state protein levels (data not shown). Control point mutant, $S-F_{pk}3-FADD_{125}V82$, was also unable to trigger apoptosis following dimerization (Fig. 25B). Thus, crosslinking the DED of FADD is sufficient to trigger the Fas pathway.

To quantitate the differences in specific and basal activities between AP1903-inducible

10   versions of caspases 1, 3 and 8, FADD, and Fas, equivalent amounts of each expression vector were transfected into Jurkat cells. Twenty hours after AP1903 administration, SEAP activity was determined as above (Fig 25C) and results were further normalized to drug-free control wells (Fig. 25D). Consistent with all previous experiments, CID-independent basal toxicities had the following ranking: Fas, caspase-8, caspase-1 > $FADD_{125}$ > caspase-3. (The

15   low, but reproducible, level of autotoxicity due to overexpression of non-chimeric FKBP12 (e.g. $S-F_v1-F_{vls}1$) is relieved by adjacent protein domains or by CIDs and probably reflects interaction with a subset of cytoplasmic proteins.) Sensitivity to AP1903 follows a somewhat different order than basal toxicity: caspase-1 ($IC_{50} \sim 50$ pM) > Fas, FADD, caspase-8 ($IC_{50} \sim$ 200 pM) > caspase-3 ($IC_{50} \sim 2$ nM). Thus, caspase-1 is likely to be the most effective ADS

20   for most applications due to its exquisite sensitivity, while caspase-3 may be more appropriate when long-term expression is required due to low basal activity.

EXAMPLE 14

Plasma membrane targeting of caspase-3 increases its CID sensitivity and basal activity.

Since FKBP/caspase-3 chimeras display very low basal activity, we considered the

25   possibility that intracellular localization of caspase-3 might increase CID sensitivity without a commensurate increase in basal toxicity. Therefore, $F_v2-Casp3$ was fused to a myristoylation-targeting sequence (M) as in $M-F_v2-Casp3$, a mitochondrial-targeting sequence as in $Mas70_{34}-F_v2-Casp3$, or a nuclear-localization sequence as in $N2-F_v2-Casp3$. Once again, the various

constructs were transfected into Jurkat cells and assayed for inducible apoptosis. Surprisingly, only the plasma membrane-localized chimeric caspase-3 was significantly more sensitive to AP1903 than the non-localized construct, S-F_v2-Casp3 (IC_{50} ~ 300 pM vs. ~ 3 nM; Fig. 26A). Moreover, M-F_v2-Casp3 was significantly more autotoxic than the other Casp3 constructs even when four-fold less plasmid was transfected (Fig. 26A). While reducing the expression levels of M-F_v2-Casp3 reduces basal activity, AP1903 sensitivity disappears before basal activity does, rendering low, completely non-toxic levels insufficient for triggering apoptosis (Fig. 26B). Further, we observed that plasma membrane-localized FADD and caspase-8 were even more autotoxic than membrane-localized caspase-3, consistent with our observations that soluble forms of these proteins have higher basal activity than caspase-3 chimeras.

To ensure that the (M, Mas70$_{34}$, and N2) targeting sequences used in this study conferred predicted localization to heterologous proteins, immunofluorescence was performed on cells transiently transfected with the differentially targeted, HA-tagged caspase-3 alleles or with epitope (E)-tagged control proteins. Since intracytoplasmic staining in Jurkat cells is difficult to visualize due to a low cytoplasm:nucleus ratio, caspase-3-sensitive HeLa cells were used (MacCorkle et al., 1998). As expected, nontargeted S-F_v2-Casp3-E is distributed throughout the cytoplasm (Fig. 26C); however, staining is somewhat punctate, suggesting possible intracellular membrane interactions. Plasma membrane targeted M-F_v2-Casp3-E stains at the plasma membrane; however, transfected cells are primarily shrunken and apoptotic, reflecting the high basal toxicity of this construct (Fig. 26D). Mitochondria-targeted Mas70$_{34}$-F_v2- Casp3-E stains in a perinuclear punctate pattern consistent with mitochondria staining (Fig. 26E), and nuclear-targeted N2-F_v2-Casp3-E stains in the nucleus (Fig. 26F). Control constructs, S-F_v2-E (Fig. 26G), M-F_v2-E (Fig. 26H), Bcl-x_L-E (Fig.26I), and Gal4-VP16-E (Fig. 26J), all localized to their predicted intracellular locations.

EXAMPLE 15

Nuclear-targeted caspases trigger apoptosis.

Since multiple caspase targets are localized in the nucleus, such as poly(ADP-ribose) polymerase (PARP), lamin A and B, DNA-dependent protein kinase catalytic subunit (DNA-

36

PK$_{cs}$), histone H1, MDM2, and topoisomerases, it is not surprising that nuclear activation of caspase-3 can trigger apoptosis. In order to test whether caspase-3 is unique in this ability, we also targeted caspase-1 and 8 to the nucleus and triggered their activation with AP1903. Interestingly, all three caspases were fully functional in the nucleus and had basal activities and

5   AP1903 sensitivities similar to their cytoplasmic activities (Fig. 27A,B). Although immunofluorescence studies suggested that nuclear targeting is efficient, we cannot rule out that a small amount of cytoplasmic protein is responsible for this cytotoxicity. To minimize this possibility we titrated both cytoplasmic and nuclear F$_v$2-Casp3 and compared their AP1903 sensitivities. Consistent with localization studies and Fig. 26A, N2-F$_v$2-Casp3 can

10   trigger apoptosis with a similar AP1903 dose response relative to S-F$_v$2-Casp3, even at low levels (Fig. 27C). Nuclear N2-F$_v$-F$_{vls}$-FADD$_{125}$, however, was unable to activate apoptosis as efficiently as cytoplasmic S-F$_v$-F$_{vls}$-FADD$_{125}$, likely reflecting the fact that its normal interaction with cytoplasmic caspase-8 does not normally occur in the nucleus (Fig. 27D). Thus, cleavage of nuclear substrates by caspases in intact cells is sufficient to trigger

15   apoptosis.

We find that dimerization of caspase-3 is sufficient for maximum CID sensitivity, while higher order multimerization is somewhat more efficient for caspase-1 activation. We also find that optimized activation of caspase-1, -8, and FADD$_{125}$ by AP1903 (but not the larger CID, FK1012) requires a short G-S-G-G-G-S linker between the cognate CBD (i.e. F$_v$) and the

20   pro-caspase. The crystal structure of AP1903 bound to two F$_v$s reveals that the FKBP12$_{V36}$ moieties are brought into closer proximity than the two FKBP12 moieties of FK1012A/FKBP12 (M. Gilman, personal communication). Thus, the more "intimate" AP1903-mediated F$_v$ interactions may "lock" crosslinked chimeric proteins into conformations that are incompatible with their activation. Interestingly, constructs with two interdomainal

25   linkers (e.g. S-F$_{vls}$2-Casp3) or with a longer G-G-S-G-G-G-S-G-G-G linker (data not shown) are less sensitive to activation, perhaps due to too much flexibility. This may imply that CIDs do more than increase the proximity of proteins; they could also hold proteins in the correct (or incorrect) orientation for activation. Further, we find that plasma membrane localization

37

of conditional caspase-3, 8 or $FADD_{125}$ increases their sensitivity for AP1903 by about

tenfold, while simultaneously increasing their basal activities. Interestingly, mitochondrial

localization of $Mas70_{34}-F_v2-Casp3$ did not increase its basal activity relative to cytoplasmic S-

$F_v2-Casp3$ even though some anti-apoptosis caspase-3 targets, like Bcl-2 and Bcl-x_L are

5   mitochondria localized (Cryns et al., 1998). Perhaps the topography of the mitochondrial

outer membrane, distinct membrane fluidity, or large surface area may reduce the local

concentration of $Mas70_{34}-F_v2-Casp3$ relative to $M-F_v2-Casp3$.

EXAMPLE 16

Construction of gene therapy vectors expressing CID-apoptosis factors.

10   Any method of delivering a nucleic acid encoding a chemically inducible apoptosis

factor may be used to practice the present invention. These methods may involve the use of a

gene therapy vector. A gene therapy vector is any molecule which, when delivered to a target

cell, is capable of causing the expression of a desired molecule. In the instant invention, the

desired molecule is the chemically inducible apoptosis factor. Preferred embodiments of gene

15   therapy vectors include viruses, plasmids and fragments of nucleic acid. The chemically

inducible apoptosis factor may be included in the vector to be used directly as the therapeutic

gene or may be incorporated into the gene therapy vector as an "artificial death switch" or

safety mechanism.

             Those skilled in the art will readily appreciate that molecules other than the ADS of

20   the present invention may be incorporated into the gene therapy vector in addition to the

ADS. For example, a vector expressing the ADS and an immunostimulatory compound may

be constructed. The immunostimulatory compound may be an interleukin, cytokine, colony

stimulating factor or the like.

             In a preferred embodiment, the gene therapy vector of the present invention will be a

25   replication restricted virus. By replication restricted it is meant that the virus is not capable of

producing infective progeny virus in the target cell. In a most preferred embodiment the

replication restricted virus will be an adenovirus. In an alternative embodiment, the virus used

as a gene therapy vector may be capable of producing infectious progeny; however, such

38

progeny may be sufficiently attenuated so as to be unable to produce a symptomatic viral

disease. Other viral vectors that may be used to practice the instant invention include, but are

not limited to, vaccinia virus, herpes virus, retroviruses, adeno-associated virus and any other

virus capable of entering the specific cell type desired to be treated and expressing the desired

5   molecule.

The viral vectors of the instant invention may be administered by any route customarily

used in gene therapy applications. Thus, they may be administered intramuscularly,

parenterally, orally, subcutaneously or topically so long as they result in uptake of the vector

into the desired cell type. The viral vectors of the present invention may be administered as

10   aerosol inhalants when used to treat lung tissue or as entericly coated capsules when used to

treat intestinal tissue.

Vectors of the present invention may include regulatory sequences to control the

expression of the chemically induced apoptotic factor. These regulatory sequences may be

eukaryotic or prokaryotic in nature. They may result in the constitutive expression of the

15   apoptosis factor such that the factor is continuously expressed upon entry of the vector into

the cell. In a preferred embodiment, the regulatory sequence will be a tissue specific promoter

such that the expression of the ADS will be substantially greater in the target tissue type

compared to other types of tissue. Alternatively, the regulatory sequences may be inducible

sequences. Inducible regulatory sequences are well known to those skilled in the art and are

20   those sequences that require the presence of an additional inducing factor to result in

expression of the CID-apoptotic factor. Examples of suitable regulatory sequences include,

but are not limited to, binding sites corresponding to CID-regulated tissue-specific

transcription factors based on endogenous nuclear proteins, sequences that direct expression

in a specific cell type, the lac operator, the tetracycline operator and the steroid hormone

25   operator. Any inducible regulatory sequence known to those of skill in the art may be used in

conjunction with the present invention.

Plasmid based vectors may also be used to administer the present invention. Plasmid

vectors may be administered by any method known to those skilled in arts such as

transfection, lypofection, cell fusion, or injection at high speed. Plasmid vectors may also

contain regulatory sequences. In addition, they may contain other genes used to mark the presence of the plasmid in a cell or to select for the presence of the plasmid in a cell. Suitable marker and selection genes are known to those skilled in the art.

5   Nucleic acids may be directly used to administer the apoptosis factors of the present invention. The nucleic acid may be DNA or RNA. The nucleic acid may incorporate chemical groups that alter the physical characteristics of the nucleic acid. For example, the internucleotide phosphate ester may be optionally substituted with sulfur so as to retard the degradation of the nucleic acid molecule. The nucleic acid may be introduced into the target cell by any means known to those skilled in the art.

10   Although the present invention is particularly useful for *in vivo* applications it may also be used for *ex vivo* applications. In *ex vivo* applications, nucleic acids encoding the chemically induced apoptotic factor may be stably integrated into the genome of a cell. The cell can then be expanded to produce a population of cells containing the chemically induced apoptotic factor. Alternatively, the nucleic acids encoding the apoptosis factor may be maintained in the

15   cell but not integrated into the genome. Those of skill in the art will appreciate that this process may require the addition of various other markers and selectable resistance genes in order to ensure that the entire population of expanded cells contains the chemically induced apoptotic factor. Various markers that may be used include *hprt*, neomycin resistance, hygromycin resistance and the like.

20   Once the vector has been administered and taken up by the appropriate cell type, the vector may cause the expression of the chemically induced apoptotic factor. Once expressed, the factor can be activated by the addition of the appropriate inducing ligand. The ligand may be administered in any fashion known to those skilled in the art including intramuscularly, orally, parenterally, subcutaneously or topically so long as the ligand is brought in contact

25   with the cell containing the chemically inducible apoptotic factor.

40

EXAMPLE 17

Construction of an adenovirus expressing a chemically inducible apoptosis factor.

The E-F_v2 YAMA-E construct described previously was placed under the control of the CMV promoter and inserted into an adenoviral recombination vector. The adenoviral recombination vector contained a copy of the D1 gene from adenovirus. The CMV promoter - E-F_v2-YAMA-E construct was inserted such that the F_v2 construct was flanked on both sides by nucleotide sequences from the E1 gene.

The plasmid was transfected into adenovirus infected cells and a recombinant adenovirus expressing the chemically inducible apoptosis factor was isolated and purified by standard methods.

Figure 19 A shows a plasmid map of the adenoviral recombination vector used to construct an adenovirus expressing E-F_V2-YAMA-E under control of the CMV promoter and incorporating the 16S splice junction to improve the efficiency of mRNA processing (Takabe, *et al.* Mol. Cell. Bio. 8:466-472, 1988). Panel B slows the results of a restriction analysis of the plasmid. Figure 20 A shows a plasmid map of the plasmid used to construct a recombinant adenovirus expressing E-F_V2-YAMA-E under the control of the SRα promoter. Panel B shows the results of a restriction analysis of the plasmid.

EXAMPLE 18

Construction of Additional Adenovirus Constructs Containing Conditional Caspase 1 or 3

I.   Construction of pAdTrack-CMV-F_{vis}1-Yama-E (Fig. 28)

1.   Digest pAdTrack-CMV with Eco RV and Not I. Purify the 9.2 kb vector by agarose electrophoresis and GeneClean (Fig. 29a-29c).

2.   Digest pSH1/S-F_{vis}1-Yama-E (Fig. 32) with Eco RI and Not I. Blunt the Eco RI end. Purify the 1.2 kb fragment by agarose electrophoresis and GeneClean.

3.   Ligate the above two fragments and transform XL1-blue with the ligation. Chose several colonies, do Miniprep and check with Sal I, Not I + Eco RI, Hind III + Eco RI, Hind III + Xho I. See Fig. 29b.

II..   Construction of pAdTrack-CMV-E-F_v1-F_{vis}1-ICEst (Fig. 28)

1. Digest pAdTrack-CMV with Eco RV and Not I. Purify the 9.2 kb vector by agarose electrophoresis and GeneClean (Fig. 30a-30c).

2. Digest pSH1/S-E-F$_v$1-F$_{vls}$1-ICEst (Fig. 31) with Eco RI and Not I. Blunt the Eco RI end. Purify the 2.2 kb fragment by agarose electrophoresis and GeneClean.

3. Ligate the above two fragments and transform XL1-blue with the ligation. Chose several colonies, do Miniprep and check with Sal I, Not I + Eco RI, Hind III + Eco RI, Hind III + Xho I. See Fig. 30b.

III. Generation of ADV-GFP-CMV-Yama-E (Figs. 33 and 34)

1. Linearize 1 ug pAdTrack-CMV-F$_{vls}$1-Yama-E with Pme I. Purify it by phenol-chloroform extraction, ethanol precipitation and resuspend in 6 μl H2O.

2. Mix it with 100 μg p AdEasy-1 (Fig. 35) (in 1 μl), Co-transform 20 μl E. coli BJ5183 competent cells with GenePulser at 2,500 V, 200 Ohms, 25 uFD.

3. Pick up 20 smallest colonies. Do Miniprep and check with Pac I. Candidate clones usually yield a large fragment (near 30 kb), plus a smaller fragment of 3.0 kb or 4.5 kb.

4. Re-transform the correct recombinant plasmids into Xl1-blue. Midiprep with Qiagen kit.

5. Transfect 293 cell by the recombinant plasmid with FuGene. 4μg DNA/6μl FuGene/well (6 well-plate). Check GFP expression with fluorescent microscope.

6. Harvest the cells when 30% of them are detached. Spin down the cells; use the supernatant for next infection. Repeat infection for several rounds.

7. Collect the cells, repeat freeze/thaw/vortex four times. Purify the virus by CsCl gradient centrifuge.

IV. Generation of ADV-GFP-CMV-E-ICE (Figs. 33 and 34)

1. Linearize 1 ug pAdTrack-CMV- E-F$_v$1-F$_{vls}$1-ICEst with Pme I. Purify it by phenol-chloroform extraction, ethanol precipitation and resuspend in 6 μl H2O.

42

2. Mix it with 100 μg p AdEasy-1 (Fig. 35) (in 1 μl), Co-transform 20 μl E. coli BJ5183 competent cells with GenePulser at 2,500 V, 200 Ohms, 25 uFD.

3. Pick up 20 smallest colonies. Do miniprep and check with Pac I. Candidate clones usually yield a large fragment (near 30 kb), plus a smaller fragment of 3.0 kb or 4.5 kb.

4. Re-transform the correct recombinant plasmids into Xl1-blue. Midiprep with Qiagen kit.

5. Transfect 293 cell by the recombinant plasmid with FuGene. 4μg DNA/6μl FuGene/well (6 well plate). Check GFP expression with fluorescent microscope.

6. Harvest the cells when 30% of them are detached. Spin down the cells, use the supernatant for next infection. Repeat infection for several rounds.

7. Collect the cells, repeat freeze/thaw/vortex four times. Purify the virus by CsCl gradient centrifuge.

V. Construction of pShuttle-CMV-E-F$_v$1-F$_{vls}$1-ICEst (Figs. 37-39)

1. Digest pShuttle-CMV (Fig. 39) with Eco RV and Not I. Purify the 7.4 kb vector by agarose electrophoresis and GeneClean.

2. Digest pSH1/S-E-F$_v$1-F$_{vls}$1-ICEst with Eco RI and Not I. Blunt the Eco RI end. Purify the 2.2 kb fragment by agarose electrophoresis and GeneClean. Fig. 38.

3. Ligate the above two fragments and transform XL1-blue with the ligation. Chose several colonies, do miniprep and check with Sal I and Eco RI.

VI. Generation of ADV-CMV-E-ICE (Figs. 37-39)

1. Linearize 1 μg pShuttle-CMV- E-F$_v$1-F$_{vls}$1-ICEst with Pme I. Purify it by phenol-chloroform extraction, ethanol precipitation and resuspend in 6 μl H2O.

2. Mix it with 100 μg p AdEasy-1 (in 1 μl), Co-transform 20 μl E. coli BJ5183 competent cells with GenePulser at 2,500 V, 200 Ohms, 25 uFD.

3. Pick up 20 smallest colonies. Do miniprep and check with Pac I. Candidate clones usually yield a large fragment (near 30 kb), plus a smaller fragment of 3.0 kb or 4.5 kb.

4. Re-transform the correct recombinant plasmids into Xl1-blue. Midiprep with Qiagen kit.

5. Transfect 293 cell by the recombinant plasmid with FuGene. 4μg DNA/6μl FuGene/well (6 well-plate). Check GFP expression with fluorescent microscope.

6. Harvest the cells when 30% of them are detached. Spin down the cells, use the supernatant for next infection. Repeat infection for several rounds.

7. Collect the cells, repeat freeze/thaw/vortex four times. Purify the virus by CsCl gradient centrifuge.

EXAMPLE 19

Luciferase Assay To Determine the Effect of Different Plasmids (Fig. 40)

1. Cells were plated in 6 well-plate, 1×10^5/ well in 3 ml media (RPMI 1640 for JD-2a cells, DMEM for 293 and 293-Z4 cells) with 5% FBS, and incubated for 24 hours.

2. Cells were transfected with 2 μg DNA each (pGL2, pTrack-ICE, pTrack-YAMA, pShuttle-ICE) and FuGene(1 μg DNA/2 μl) and incubated overnight.

3. AP1903, or FK 1012,or AP20187 was added at a final concentration of 50 nM and cultures were incubated 24 hours.

4. Cells were lysed and checked for luciferase activity on a luminometer.

The results are shown at Figure 40.

EXAMPLE 20

Assay To Determine Effects of Using Different Viruses (Figs. 41-45)

1. Cells were plated in 24 well-plate, $2X10^4$ to $4X10^4$ cells/well in 1 ml media (RPMI 1640 for JD-2a, LNCaP and PC3 cells; DMEM for Tramp, T-C2 and T-C2G cells) with 5% FBS, and incubated until the cell number doubled.

2. Cells were infected with the virus at different MOI and incubated overnight.

3. AP1903, or FK 1012,or AP20187 was added at a final concentration of 50 nM and cultures were incubated 24 hours.

4. Cells were fixed with 1% glutaraldehyde for 15 min.; stained with 0.5% crystal violet for 20 min.; washed with H2O for 30 min.; air dried; resolved with 200-500 ul/well Soreson's Solution for 5 min.; transfered 60—100 μl to each well of 96-well plate and read OD at 570 nm. Results are shown in Figs 42-45.

EXAMPLE 21

Replication deficient (Δ E1) adenoviral vectors expressing green flourescent protein and conditional Caspase 1 (ICE) or Caspase 3 (YAMA) were engineered. These vectors independently express green fluorescent protein so that infected cells are easily identified by their green color under fluorescent microscopy. These vectors were tested for their ability to induce apoptosis *in vitro* in a SMC line derived from a patient with BPH upon administration of a non-toxic, lipid-permeable, divalent FK506 analog (AP1903).

40,000 JD-2a cells per well were plated in 24-well plates and infected at a multiplicity-of-infection (MOI) of ~25 with Adv-F_V1-YAMA, an adenoviral vector expressing CID-regulated YAMA. After 24 hours, culture media was changed to control media ± 50nM AP1903 for an additional 24 hours, and the cells were viewed under fluorescent microscopy. All of the cells incubated with virus and maintained in control media appeared green, and were clearly attached and viable, similar to non-fluorescent non-infected JD-2a cells (Fig. 47b). However, >99% of the cells incubated with virus and maintained in 50nM AP1903 were either dead or in the process of undergoing apoptosis (Fig 47c). Fig. 47a shows uninfected, untreated culture of JD-2a cells.

EXAMPLE 22

ADV-FKBP/ICE effectively kills JD-2a BPH cells and PC-3 Prostate cancer cells

1. Cells were plated in 24 well-plate, $2X10^4$ to $4X10^4$ cells/well in 1 ml RPMI 1640 media with 5% FBS, and incubated until the cell number doubled.

2. Cells were infected with the virus at different MOI and incubated overnight.

3. AP1903 was added at a final concentration of 50 nM and cultures were incubated 24 hours. Control cultures did not receive AP1903.

4. Cells were fixed with 1% glutaraldehyde for 15 min.; stained with 0.5% crystal violet for 20 min.; washed with H2O for 30 min.; air dried; resolved with 200-500 ul/well Soreson's Solution for 5 min.

Results are shown in Figs 48 and 49. Addition of 50nM AP1903 is indicated by (+). Figure shows that ADV-FKBP/ICE kills JD-2a BPH cells at higher MOI even without the CID. Figure 48 shows that ADV-FKBP/ICE effectively kills PC-3 prostate cancer cells at MOIs of 5 and greater upon the administration of the CID.

EXAMPLE 23

Therapeutic applications of chemically inducible apoptosis factors

In general any therapeutic application currently practiced using the HSV-tk/ganciclovir system can be practiced using the present invention. The chemically inducible apoptosis factors may be incorporated into any delivery vector presently incorporating the HSV-tk gene and the vector may be applied in the same fashion as presently employed. In order to induce apoptosis, the appropriate chemical inducer of dimerization is administered. Specific examples of types of tumor cells that may be treated with gene therapy vectors expressing the ADSs of the present invention are presented below. Therapeutic applications will be developed using the models systems described, or any equivalent model system. Those skilled in the art will readily appreciate that it may be necessary to optimize certain parameters such as the dose of the gene therapy vector, dose of the dimerization ligand and the timing of the application of the dimerization ligand after the inoculation of gene therapy vector. Such optimization is well within the purview of ordinary skill in the art. The examples presented

46

below are for illustrative purposes only are not intended to be an exhaustive recitation of all possible therapeutic applications. Other therapeutic applications will be obvious to those skilled in the art upon reading the present application and are within the scope of this invention.

5   One example of the use of the chemically inducible apoptosis factors of the present invention is in the treatment of prostate cancer. A gene therapy vector expressing the chemically inducible apoptosis factor can be directly injected into the prostate and then activated with the appropriate ligand. Optionally, the expression of the chemically inducible apoptosis factor may be controlled by the prostate specific antigen (PSA) promoter. In a

10   preferred embodiment, the gene therapy will be a recombinant adenovirus vector. As a model system, mice may be injected with a suitable prostate cancer cell line, such as RM-1. About 4 X 10^6 cells may be subcutaneously injected into BALB/c mice to induce tumor formation. After a period of time to allow growth of the tumor, the mice will be injected with a gene therapy vector. In a preferred embodiment the vector will be a recombinant adenovirus vector

15   constructed using the plasmids of Figures 19 and 20. After a suitable period of time, apoptosis will be induced in the treated cells by the addition of a chemical inducer of dimerization.

          Another example of the use of therapeutic applications of the ADSs of the present invention is the use of gene therapy vectors expressing and ADS to treat gliomas. A rat

20   glioma model system can be constructed by injection of a suitable glioma cell line, such as 9L, into rats to induce tumor formation. The tumor cells may be injected directly into the brain in a stereotactic inoculation of about 1 X 10^4 9L cells. Alternatively, subcutaneous injections of about 1 X 10^6 9L cells may be used. After a suitable time period to allow growth of the tumor, the rats will be inoculated with a gene therapy vector. In a preferred embodiment, the

25   gene therapy vector will be a recombinant adenovirus expressing an ADS. Optionally, the expression of the ADS will be controlled by a tissue specific promoter. After inoculation with gene therapy vector, the animals will be injected with an appropriate dimerization ligand.

          A gene therapy vector expressing an ADS of the present invention may be used to treat squamous cell carcinomas. A nude mice model system may be constructed by injection

of a suitable squamous carcinoma cell, such as USMSCC29 cells, into nude mice to induce tumor formation. The tumor cells, about 5 X 10^6 cells, may be injected into the flanks of the animals. After a suitable time period to allow growth of the tumor, approximately 2 weeks,

5   the mice will be inoculated with a gene therapy vector. In a preferred embodiment, the gene therapy vector will be a recombinant adenovirus expressing an ADS. Optionally, the expression of the ADS will be controlled by a tissue specific promoter. After inoculation with gene therapy vector, the animals will be injected with an appropriate dimerization ligand to induce apoptosis of the tumor. Those skilled in the art will readily appreciate that it may be necessary to optimize certain parameters such as the dose of the gene therapy vector, dose of

10   the dimerization ligand and the timing of the application of the dimerization ligand after the inoculation of gene therapy vector. Such optimization is well within the purview of ordinary skill in the art.

Gene therapy vectors expressing the ADSs of the present invention may be used to treat breast cancer. A suitable model system may be constructed by injecting athymic mice

15   with a suitable breast cancer cell line, such as MDA-MB-435A. Tumors may be induced by the intraperitoneal injection of about 5 X 10^6 MDA-MB-435A cells. After a suitable period to allow tumor formation, about 10 days, a gene therapy vector of the present invention will be injected into the mice. Subsequently, the mice will be injected with the chemical inducer of dimerization to induce apoptosis in the cells carrying the gene therapy vector. In a preferred

20   embodiment, the gene therapy vector will be a recombinant adenovirus expressing the ADSs of the present invention. Optionally, the expression of the ADS may be controlled by a tissue specific promoter.

EXAMPLE 24

Treatment of benign hyperproliferative disorders using gene therapy vectors expressing ADSs

25   of the present invention.

The gene therapy methods of the prior art that use suicide genes to eradicate cancerous cells are entirely unsuited to applications involving benign hyperproliferative disorders. The high risk associated with the toxic pro-drugs of the prior art restricts the

therapeutic applications of these methods to use in life threatening situations. In contrast, gene therapy vectors expressing the ADSs of the present invention are well suited to applications involving the treatment of benign hyperproliferative disorders by virtue of the non-toxic nature of the constructs themselves as well as the non-toxic nature of the chemical

5   inducer of dimerization.

BPH is one example of a benign hyperproliferative disorder that is amenable to treatment using gene therapy methods based on the ADSs of the present invention. As demonstrated in Examples 6-8, gene therapy vectors expressing the ADSs of the present invention are extremely effective in killing a wide variety of cell types, including those derived

10   from BPH. A gene therapy vector expressing an ADS may directly injected into a prostate gland of a patient suffering from BPH. After a suitable period of time to allow the gene therapy vector to be taken up by the treated cell, the patient will be given a chemical inducer of dimerization to induce apoptosis in the treated tissue. In a preferred embodiment, the gene therapy vector will be a recombinant adenovirus expressing an ADS. In other preferred

15   embodiments the expression of the ADS will be under the control of a prostate specific promoter. In a most preferred embodiment, the expression of the ADS will be controlled by the prostate specific antigen promoter.

                                    EXAMPLE 25

Construction of tumor specific ADSs.

20   The ADSs of the present invention can be used to specifically ablate cells of tumors by incorporating tumor specific promoters into the gene therapy vectors. The expression of the ADS will be placed under the control of a promoter that is active only in the target tumor cells.

For example, to construct a gene therapy vector that specifically ablates melanoma

25   cells, the expression of the ADS of the present invention can be placed under the control of the tyrosinase promoter (Vile, et al. Cancer Res. 53:962-967, 1993). The construction of a melanoma specific, gene therapy vector can be accomplished using techniques well known in the art. The tyrosinase promoter can be operatively connected to a cassette comprising one or

more chemical inducer binding domains fused in frame to a protein that induces apoptosis upon dimerization. The cassette, including the tyrosinase promoter, is then inserted into a plasmid for recombination into an adenovirus. Typically this is accomplished by inserting the cassette into a plasmid that contains a copy of the adenovirus E1 gene.

5   The cassette is inserted into the E1 gene such that portions of the E1 gene flank both ends of the cassette. The resulting plasmid is used to transfect cells infected with adenovirus resulting in the inclusion of the cassette into the adenovirus by homologous recombination. The construction of adenoviruses incorporating heterologous genes by this method is well known to those of skill in the art. The method used by Chen, et al. (PNAS 92: 2577-2581,

10   1995, which is specifically incorporated herein by reference) for the construction of an adenovirus expressing the HSV-tk gene may be used by substituting the gene encoding the ADS of the present invention for the HSV-tk gene.

Those skilled in the art will readily appreciate that gene therapy vectors that specifically target other types of tumors can be constructed by the use of promoters specific

15   for the type of tumor targeted. Others tumor specific promoters that may be used in the present invention include, but are not limited to, the prostate specific antigen promoter for targeting prostate tumors (Ko, et al. Proc. Am. Assn. Cancer Res. 37:349, 1996), the human surfactant protein A promoter for targeting non-small-cell lung carcinomas (Smith, et al. Hum. Gene Therapy 5:29-35, 1994), the glucose related protein 78 (grp78) promoter for

20   targeting fibrosarcomas (Gazit, et al. Cancer Res. 55:1660-1665, 1995) and the carcinoembryonic antigen (CEA) promoter to target tumor cells like pancreatic carcinoma cells (DiMaio, et al. Surgery 116:205-213, 1994). Any promoter that is substantially more active in tumor cells than in non-tumor cells may be used to practice the present invention.

EXAMPLE 26

25   <u>Caspase-based suicide genes can trigger apoptosis in prostate cancer cell lines derived from tumors from intact and castrated TRAMP and MPR model mice.</u>

DESIGN: We will determine whether progression to androgen-independence affects sensitivity to caspase-mediated apoptosis. Apoptosis assays will be performed on prostate

50

cancer cells derived from both the TRAMP model and the MPR model following CID-

mediated caspase activation. The efficacy of caspase-mediated apoptosis in clones from intact

mice will be compared to TRAMP tumors isolated from castrated mice or RM cells passaged

in castrated mice. Finally, direct bystander killing will be investigated.

5   METHODS: TRAMP-C2 cells (Foster, B.A., et al. (1997) *Cancer Res* 57, 3325-3330),

RM-1 and RM-9 cells (Baley, P.A., et al. (1995) *J Steroid Biochem Mol Biol* 52, 403-413)

will be transduced with recently constructed retrovirus or adenovirus (ADV) vectors

expressing CID-responsive ICE and YAMA proteins. Twenty-four hours after transduction,

cells will be treated with up to 100 nM AP1903. Control cells will be mock transduced or

10   mock treated. Alternatively, these experiments will be performed in tumors from castrate

mice. TRAMP mice will be castrated at twelve weeks and androgen-independent tumors will

be removed at 24 weeks as described previously (Gingrich, J.R., et al. (1997) *Cancer Res* 57,

4687-4691). Androgen-independent RM cell lines have been previously characterized (Baley,

P.A., et al. (1995) *J Steroid Biochem Mol Biol* 52, 403-413). Twenty hours after CID

15   treatment, cells will be analyzed for apoptosis by DNA laddering, annexin V-FITC staining

followed by flow cytometry, and by the TUNEL assay. Bystander killing will be based on the

minimum fraction of FKBP/caspase-expressing cells needed to trigger apoptosis in >95% of

the cells in a confluent culture following CID treatment. We will test apoptosis by multiple

assays because the exact biochemical changes during apoptosis can differ in distinct tissues.

20   EXPECTED RESULTS: Since we have previously demonstrated that TRAMP-C2 cells,

RM-1 and RM-9 cells are sensitive to CIDs following transient transfection of CID-responsive

ICE and YAM A plasmids, virally transduced cells should be similarly sensitive to CIDs.

Further, progression to androgen-independence should not effect ICE and YAMA sensitivity

because these caspases can trigger apoptosis even in the presence of relatively high levels of

25   Bcl-X_L. The observation of a bystander effect in culture will be novel, as it has not been

previously reported.

EXAMPLE 27

ADV-FKBP/ICE effectively kills TRAMP-C2 cells in vivo

Referring to Fig. 50, mice were subcutaneously injected with $2x10^6$ TRAMP-C@ cells
to induce tumor formation. On day 12, tumors were injected with $\sim 10^{10}$ of ADV-GFP/F$_v$2-
Casp1. On day 16, the mice were intraperitoneally injected with 50μg of CID. Control cells
were be mock transduced or mock treated. Twenty hours after CID treatment, tumors were
resected, and analyzed. Figures 51 and 52 show transduced, untransduced, treated and
untreated tumor sections. Referring to Fig. 51, the tumor section showing no ICE + CID
appears healthy; while the tumor sections treated with ICE and no CID are showing the
effects of apoptosis. Figure 52 shows the dramatic apoptotic effect that results upon
administration of a CID.

EXAMPLE 28

Determine the safety and efficacy of gene therapy using ADV vectors expressing inducible
ICE and YAMA in the TRAMP and MPR orthotopic prostate cancer models.

DESIGN: We plan to perform *in vivo* gene therapy studies similar to those previously
reported using HSV-tk/GCV in the MPR model system (Eastham, J.A., et al. (1996) *Hum
Gene Ther.* 7, 515-523). Subcutaneous tumors will be generated by injection of RM-1 cells
into syngeneic, C57BL/6 male hosts and inoculated with escalating doses of HSV-tk virus,
inducible YAMA virus, inducible ICE virus, or a control β-gal virus ($5x10^7$ to $1x10^9$ pfu).
The mice will receive GCV (HSV/tk arm) or AP1903 (ICE/YAMA arms) twice daily for 6
days and will be sacrificed when tumor volumes exceed 2.5 cm^3 or when they appear in
distress. Tumors will be assessed for final volume, and histologically for apoptotic index and
extent of tumor necrosis. Finally, mean survival in days will be compared in the four
treatment arms.

METHODS: $4x10^6$ RM-1 cells will be injected s.c. in 12-week-old C57BL/6 mice. Twenty
mice will be injected in each treatment arm. Tumor volumes will be calculated by the formula
for a rotational ellipsoid. To ascertain a target therapeutic viral dose, escalating viral doses
from $5x10^7$ to $1x10^9$ pfu will be injected directly into tumors when the volume is
approximately 50 mm^3. Twelve hours following viral injection, each animal will be treated

with intraperitoneal (ip) injections of GCV at a dose of 10 mg/kg body weight or AP1903 at a dose of 2 mg/kg body weight every 12 hr for 6 days. Tumor volume will be assessed every other day, and mice will be sacrificed when tumor volume exceeds 2.5 cm³. Tumors will be assessed histologically or with the TUNEL technique to label cells undergoing apoptosis.

5   EXPECTED RESULTS: It is anticipated that inducible ICE/YAMA constructs will be able to trigger apoptosis more extensively and more quickly in prostate cancer cells, due to their slow growth relative to other tumor types and the ability of caspases to trigger rapid apoptosis.

EXAMPLE 29

10   Triggering apoptosis in orthotopic tumor cells will reduce the number of spontaneous metastasis.

DESIGN: We plan to perform *in vivo* gene therapy studies similar to those previously reported using HSV-tk/GCV in the orthotopic MPR model system (Hall, S.J., et al. (1997) *Int. J. Cancer* 70, 183-187). Orthotopic tumors will be generated by injection of RM-1 cells

15   into the prostates of syngenic male hosts. Typically this aggressive model of prostate cancer results in distress or death of the host by 16-17 days post-inoculation. In contrast to the s.c. model (SA2), orthotopic tumors result in documented metastatic activity in over 80% of animals by 16-17 days with the highest activity in the pelvic and retroperitoneal (RP) lymph nodes and the lowest activity in the lung. Since tumors are metastatic by 2 weeks post-

20   inoculation, at 7 days post-inoculation, tumors will be injected with an appropriate dose, determined in SA2, of HSV-tk virus, inducible YAMA virus, inducible ICE virus, or a control β-gal virus. The mice will receive GCV (HSV/tk arm) or AP1903 (ICE/YAMA arms) twice daily for 6 days, and sacrificed at 14 days. A careful autopsy for gross and microscopic metastasis will be performed. Survival studies will be performed with animals sacrificed when

25   in distress. Mean survival in days will be compared in the four treatment arms.

METHODS: Initially, 1000 RM-1 cells in 10 µl will be injected directly into the right or left lobe of the dorsolateral prostate of adult syngeneic male C57BL/6 mice. 20 mice in each treatment arm will be injected. Tumor volumes will be calculated as above. Tumors will be

53

weighed, and the pelvic and RP lymph nodes and samples of lungs will be excised and processed histologically. Animals will be scored as having metastasi if any lymph node and/or lung has microscopic evidence of metastasis.

EXPECTED RESULTS: We expect to see a reduction in spontaneous metastasis, which is inversely proportional to the efficiency of the method of killing. Since the efficacy of HSV-tk/GCV treatment can be reduced by checkpoint proteins like Bcl-2, which are also associated with progression to metastatic cancer, we expect Bcl-2-insensitive, caspase-mediated apoptosis to be a more anti-metastatic.

EXAMPLE 30

Triggering apoptosis in s.c. tumor cells will augment a systemic immune response against a second-site tumor.

DESIGN: Tail vein inoculum challenges will be performed to ascertain whether system anti-metastatic activity can be induced against a second tumor challenge following a single treatment with inducible-YAMA/AP1903 or inducible-ICE/AP1903, as compared to HSV-tk/GCV as previously reported (Hall, S.J., et al. (1997) *Int. J. Cancer* 70, 183-187).

METHODS: Using the s.c. model, tumors will be initiated as described in SA2, and treated appropriately with either GCV or AP1903 for 6 days. On day 10 post-tumor inoculation, s.c. tumors will be surgically removed. Two weeks later, 40,000 RM-1 cells will be injected *via* the dorsolateral tail vein. Animals will be euthanized 2 weeks later. The lungs will be removed and fixed in Bouin's solution. Individual visible lung metastases will be counted with the aid of a dissecting microscope, and the three treatment arms compared.

EXPECTED RESULTS: We anticipate a larger reduction in metastasis after caspase treatment relative ot HSV-tk treatment. This should reflect a more robust anti-tumor immune response initiated by the efficient transfer of putative tumor antigens to APCs following caspase-mediated apoptosis. Since s.c. tumors do not have the same local environment as orthotopic tumors with regards to extracellular matrix factors, microvasculature and local APCs, we will repeat these experiment in an orthotopic model if significant anti-metastatic effects (or differences) are not seen.

EXAMPLE 31

Construction of animals specifically deleted in various cell types.

The present invention can be used to create animals that are specifically deleted of a certain cell type. A recombinant animal, for example a mouse, can be constructed so that an ADS under the control of a tissue specific promoter is stably incorporated into the genome. This will result in an animal that expresses an ADS in a single cell type. In the absence of a chemical inducer of dimerization, the cells expressing the ADS will develop normally. When desired, the specific cells may be deleted by the addition of the inducer.

Animals of this type will permit the elucidation of the roles of various types of cells. This will be particularly useful in the elucidation of the roles of cells of the immune system. By varying the timing of the deletion of the cell type expressing the ADS, the role of that cell type in development may also be ascertained.

Examples of types of cells that might be specifically deleted include, but are not limited to, ß-islet cells of the pancreas to develop a diabetes model and melatonin-containing cells of the *substantia nigra* to develop a model for Parkinson's disease. This approach will also be useful in studying the roles of various cells of the immune system. Other cell types that may be specifically deleted include, but are not limited to, cardiac myocytes to create a model for cardiac disease, thyroid cells for a hypothyroidism model, pituitary cells for growth hormone deficiencies, osteoblasts for osteoporosis, kidney cells for renal failure, liver cells for hepatitis and the cells of any endocrine organ.

Transgenic animals will be made using techniques well known to those of skill in the art. In brief, an mammalian expression vector will be micro-injected into the male pro-nuclei of a fertilized embryo. The mammalian expression cassettes will typically include the cDNA encoding the ADS subcloned 3' of a tissue specific promoter/enhancer sequence. In a preferred embodiment, the tissue specific promoter/enhancer sequence will be followed by a splicing donor acceptor sequence. Several reports demonstrate that splicing is important for efficient mRNA processing and nuclear export. The mammalian expression vector may also include a polyadenylation sequence 3' to the DNA sequence encoding the ADS.

Injected embryos will be implanted into pseudo-pregnant females. Tail DNA from all live pups will be analyzed for integration. Transgenic "founder" mice will be further bred and analyzed for germline transmission of the DNA.

EXAMPLE 32

5   Treatment of arteriosclerosis using adenoviruses expressing an ADS.

Recombinant adenoviruses expressing ADS can be used to treat atherosclerosis. Atherosclerosis is characterized by a proliferation of smooth muscle cells. As demonstrated by their ability to kill smooth muscle cells derived from BPH, the chemically inducible apoptosis factors of the present invention may be used to ablate the smooth muscle cells

10   present in arteriosclerotic tissue. A gene therapy vector expressing an ADS of the present invention may be directly applied to the interior wall of a sclerotic vessel using methods known to those skilled in the art. An example of such a method is provided by Nabel, *et al.* U.S. Patents 5,698,531, 5,328,470 and 5,707,969 which are specifically incorporated herein by reference. In brief, a solution containing the gene therapy vectors of the present invention

15   is delivered to the sclerotic portion of the vessel by using a catheter. The specific segment is isolated and the solution is infused into the space adjacent to the lesion for a period of time sufficient to permit the uptake of the vector into the target tissue. Subsequently, dimerization of the ADS is induced by application of the appropriate ligand and the cells taking up the gene therapy vector will undergo apoptosis.

20   EXAMPLE 33

Use of ADSs as safety switches in gene therapy vectors.

The previous examples had shown the utility of the ADSs of the present invention as the primary active agent in the treatment of various disorders. In addition to their use in this fashion, the ADSs of the present invention may be incorporated into gene therapy vectors as

25   safety switches. This mode of use will be particularly important in gene replacement therapies.

Gene replacement therapies differ from the preceding examples in that stable, long-term expression of the replacement gene is required. Gene replacement therapies are generally most applicable to those disorders caused when a single gene is either absent or malfunctioning. A gene therapy vector expressing a functional allele of the

5   missing/malfunctioning gene is introduced into the affected cells. To ensure the required long-term expression, replacement therapies typically are conducted using retroviruses as gene therapy vectors with the result that the replacement gene is inserted into the genome of the treated cell. In the process of inserting the replacement gene into an affected cell, there is a possibility that some of the insertions may result in a malignant transformation of the cell.

10   The present invention is well suited to provide a necessary measure of safety in this case. Genes encoding the ADSs of the present invention may be incorporated into the retroviral gene therapy vector along with the therapeutic gene so that stable integration of the retrovirus results in the expression of both genes. In the event that a malignant transformation occurs, a chemical inducer of dimerization can be administered to delete the cells that contain

15   the retrovirus.

CONCLUSION

As gene therapy comes of age and vectors move from the laboratory to the clinic, the need for safety is becoming a serious consideration. The instant invention, ADSs based upon apoptosis factors, may lead to clinically suitable suicide switches for these vectors for the

20   following reasons: (i) They can be made exclusively from syngeneic proteins, reducing the likelihood of triggering an immune response; (ii) they are effective in a wide variety of cells, are not restricted to dividing cells, and are not significantly blocked by intracellular checkpoint genes, such as $Bcl-x_L$; and (iii) CIA works with a panel of distinct dimerizing agents that are not currently used for any other purpose and will therefore be useful for regulating viability in

25   multiple independent target tissues (5,8). Finally, CIA may be useful for developmental studies or for treating both malignant and benign hyperproliferative disorders, such as cancer and BPH.

The present invention has been described in terms of preferred embodiments. Those skilled in the art will readily appreciate that these embodiments are for illustrative purposes and are not intended to limit the present invention in any way. Various modifications or changes will be suggested to those skilled in the art by the present application and such

5   modifications are within the spirit of the present invention and within the scope of the appended claims. All publications mentioned in this disclosure are specifically incorporated herein by reference.

58

REFERENCES

1.   Moolten, F.L. (1986) *Cancer Res.* **46**, 5276-5281.

2.   Culver, K.W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E.H. & Blaese, R.M. (1992) *Science* **256**, 1550-1552.

3.   Matthews, T. & Boehme, R. (1988) *Rev. Infect. Dis.* **10 Suppl 3**, S490-S494.

4.   Ogasawara, J., Suda, T. & Nagata, S. (1995) *J. Exp. Med.* **181**, 485-491.

5.   Spencer, D.M., Belshaw, P.J., Chen, L., Ho, S.N., Randazzo, F., Crabtree, G.R. & Schreiber, S.L. (1996) *Current Biology* **6**, 839-847.

6.   Liles, W.C., Kiener, P.A., Ledbetter, J.A., Aruffo, A. & Klebanoff, S.J. (1996) *J. Exp. Med.* **184**, 429-440.

7.   Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T. & Nagata, S. (1993) *Nature* **364**, 806-809.

8.   Belshaw, P.J., Spencer, D.M., Crabtree, G.R. & Schreiber, S.L. (1996) *Chem. Biol.* **3**, 731-738.

9.   Smith, C.A., Farrah, T. & Goodwin, R.G. (1994) *Cell* **76**, 959-962.

10.   Yuan, J. (1997) *Curr. Opin. Cell Biol.* **9**, 247-251.

11.   Hengartner, M.O. (1997) *Nature* **388**, 714-715.

12.   Kroemer, G. (1997) *Nat. Med.* **3**, 614-620.

13.   Spencer, D.M., Wandless, T.J., Schreiber, S.L. & Crabtree, G.R. (1993) *Science* **262**, 1019-1024.

14.   Spencer, D.M. (1996) *TIG* **12**, 181-187.

15.   Crabtree, G.R. & Schreiber, S.L. (1996) *Trends. Biochem. Sci.* **21**, 418-422.

16.   Duan, H., Chinnaiyan, A.M., Hudson, P.L., Wing, J.P., He, W.W. & Dixit, V.M. (1996) *J. Biol Chem* **271**, 1621-1625.

17.   Rosen, M.K., Yang, D., Martin, P.K. & Schreiber, S.L. (1993) *JACS* **115**, 821-822.

18.   Spencer, D.M., Graef, I., Austin, D.J., Schreiber, S.L. & Crabtree, G.R. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 9805-9809.

19.   Northrop, J.P., Ullman, K.S. & Crabtree, G.R. (1993) *J. Biol Chem* **268**, 2917-2923.

20.   Henkart, P.A. (1996) *Immunity* **4**, 195-201.

21.   Boldin, M.P., Varfolomeev, E.E., Pancer, Z., Mett, I.L., Camonis, J.H. & Wallach, D. (1995) *J. Biol. Chem.* **270**, 7795-7798.

22.   Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J.L., Schroter, M., Burns, K., Mattmann, C., Rimoldi, D., French, L.E. & Tschopp, J. (1997) *Nature* **388**, 190-195.

23.   Deveraux, Q.L., Takahashi, R., Salvesen, G.S. & Reed, J.C. (1997) *Nature* **388**, 300-304.

24.   Freiberg, R.A., Spencer, D.M., Choate, K.A., Duh, H.J., Schreiber, S.L., Crabtree, G.R. & Khavari, P.A. (1997) *J. Invest. Dermat.* **108**, 215-219.

25.   Aggarwal, B.B., Singh, S., LaPushin, R. & Totpal, K. (1995) *FEBS Letters* **364**, 5-8.

26.   Freiberg, R.A., Spencer, D.M., Choate, K.A., Peng, P.D., Schreiber, S.L., Crabtree, G.R. & Khavari, P.A. (1996) *J. Biol. Chem.* **271**, 31666-31669.

27.   Veis, D.J., Sentman, C.L., Bach, E.A. & Korsmeyer, S.J. (1993) *J. Immunol* **151**, 2546-2554.

28.   Pan, G., O'Rourke, K., Chinnaiyan, A.M., Gentz, R., Ebner, R., Ni, J. & Dixit, V.M. (1997) *Science* **276**, 111-113.

29.   Boldin, M.P., Goncharov, T.M., Goltsev, Y.V. & Wallach, D. (1996) *Cell* **85**, 803-815.

30.   Muzio, M., Chinnaiyan, A.M., Kischkel, F.C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J.D., Zhang, M., Gentz, R., Mann, M., Krammer, P.H., Peter, M.E. & Dixit, V.M. (1996) *Cell* **85**, 817-827.

31.   Tewari, M., Quan, L.T., O'Rourke, K., Desnoyers, S., Zeng, Z., Beidler, D.R., Poirier, G.G., Salvesen, G.S. & Dixit, V.M. (1995) *Cell* **81**, 801-809.

32.   Chinnaiyan, A.M., O'Rourke, K., Tewari, M. & Dixit, V.M. (1995) *Cell* **81**, 505-512.

33.   Bauer, M.K., Wesselborg, S. & Schulze-Osthoff, K. (1997) *FEBS Lett.* **402**, 256-258.

34.   Chinnaiyan, A.M., Chaudhary, D., O'Rourke, K., Koonin, E.V. & Dixit, V.M. (1997) *Nature* **388**, 728-729.

35.   Zou, H., Henzel, W.J., Liu, X., Lutschg, A. & Wang, X. (1997) *Cell* **90**, 405-413.

36.   Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S.M., Ahmad, M., Alnemri, E.S. &
       Wang, X. (1997) *Cell* **91**, 479-489.

37.   Chinnaiyan, A.M., O'Rourke, K., Lane, B.R. & Dixit, V.M. (1997) *Science* **275**,
       1122-1126.

5   38.   Wu, D., Wallen, H.D., Inohara, N. & Nunez, G. (1997) *J Biol. Chem.* **272**, 21449-
       21454.

39.   Boulikas, T. (1997) *Anticancer Research* **17**, 1471-1506.

What is claimed is:

1.   A conditionally lethal molecule comprising a chemical inducer binding domain and an apoptosis inducing factor, wherein said apoptosis inducing factor is an apoptosis signal transducing factor.

2.   A conditionally lethal molecule according to claim 1, wherein said apoptosis inducing factor is an adaptor molecule.

3.   A conditionally lethal molecule according to claim 1, wherein said apoptosis inducing factor is a protease.

4.   A conditionally lethal molecule according to claim 1, wherein said apoptosis inducing factor is a caspase.

5.   A nucleic acid molecule encoding the conditionally lethal molecule of any one of claims 1-4.

6.   A nucleic acid molecule according to claim 5, further comprising a sequence coding for tissue specific expression operatively linked to a sequence coding for a conditionally lethal molecule.

7.   A gene therapy vector comprising a nucleic acid sequence coding for the expression of a conditionally lethal molecule according to anyone of claims 1-4.

8.   A gene therapy vector according to claim 7, further comprising a sequence coding for a therapeutic gene.

62

9.   A gene therapy vector according to claim 7, further comprising a sequence coding for tissue specific expression operatively linked to a sequence coding for a conditionally lethal molecule.

10.   A transgenic animal expressing a conditionally lethal molecule according to any one of claims 1-4.

11.   A method of making a transgenic animal comprising the step of micro-injecting a nucleic acid molecule encoding a conditionally lethal molecule according to any one of claims 1-4.

12.   A method of treating a disease comprising the step of administering a vector that encodes a conditionally lethal molecule according to any one of claims 1-4.

13.   A method according to claim 12, wherein the disease is a hyperproliferative disease.

14.   A method according to claim 13, wherein the hyperproliferative disease is a benign disease.

15.   A method according to claim 14, wherein the disease is a malignant disease.

16.   A method according to claim 12, wherein the disease is atherosclerosis.

17.   A method of causing regression of a tumor comprising transfecting cells of said tumor with a nucleic acid molecule encoding a conditionally lethal molecule according to any one of claims 1-4.

63

18.   A method according to claim 17 further comprising administering a
CID.

19.   A method of causing a reduction in tumor size comprising transfecting
cells of said tumor with a nucleic acid molecule encoding a conditionally lethal molecule
5   according to any one of claims 1-4.

20.   A method according to claim 19 further comprising administering a
CID.

21.   A method of causing a reduction in PSA levels comprising transfecting
cells of a tumor with a nucleic acid molecule encoding a conditionally lethal molecule
10   according to any one of claims 1-4.

22.   A method according to claim 21 further comprising administering a
CID.

23.   A method of affecting the rate of cell proliferation caused by BPH
comprising transfecting prostate cells with a nucleic acid molecule encoding a conditionally
15   lethal molecule according to any one of claims 1-4.

24.   A method according to claim 23 further comprising administering a
CID.

25.   A method of inducing apoptosis in a cell comprising transfecting said
20   cell with a nucleic acid molecule encoding a conditionally lethal molecule according to any
one of claims 1-4.

26.   A method according to claim 26 further comprising administering a CID.

27. A method for determining the biological role of a cell type, comprising transfecting a cell of said cell type with a nucleic acid molecule encoding a conditionally lethal molecule according to any one of claims 1-4 and administering a CID.

FIGURE 1

FIGURE 2

FAS cytoplasmic domain — Myristoylation-targeting domain — CID/CBD

Caspases → Death substrates → Apoptosis

FIGURE 3

FIGURE 4

FIGURE 5

FIGURE 6

FIGURE 7

FIGURE 8

FIGURE 9

FIGURE 10

F_v2-Casp-3						F_v2-Casp3/S163					
Hours						Hours					
8	4	2	1	.5	0	8	4	2	1	.5	0

100 nM

500 nM

09/647418

FIGURE 11

F_v2-Casp-3						F_v2-Casp3/S163					
AP1903 nM						AP1903 nM					
100	32	10	3.2	1	0	100	32	10	3.2	1	0

FIGURE 12

FIGURE 13

FIGURE 14

FIGURE 15

FIGURE 16

FIGURE 17

FIGURE 18

FK506

FK1012-A
(n=1)

FIGURE 19

FIGURE 20

A

B

FIGURE 21

CID-Mediated Apoptosis In BPH-derived CR-2a SMC

FIGURE 22

CID-Mediated Apoptosis in BPH derived JD SMC

FIG 23   (FIG 24 on Reverse)

Final Size: 50% or 11.1cm

09/647418

Final Size: 67%
or 7 cm

FIG 25 (FIG 26 on Reverse)

FIG 27

09/647418

Generation of Ad-GFP-CMV-YM-E
Ad-GFP-CMV-E+IC   US 99.06799

pAd Track - CMV ~ FVISI — YM-E
~E-FVI-FVISI
—ICESt

① cut pAd Track-CMV- with EcoR V + Not I

1 ug/2ul (pAd Track-CMV) + 1 ul Buffer H
+ 1ul EcoRV + 1 ul Not I , +H₂O 5ul
37°C, 2 hr.

pAdTrack-CMV
9220 bp

② cut pSH1/s — FVIS1 — YM-E with Not I + EcoRI
(got 2.2kb FVIS1-YM-E)
2ug/1.2ul (pSH1/s-FVIS1-YM-E + 2ul EcoRI
+ 2ul Buffer H, +H₂O 14.8 ul, 37°C, 1 hr.

[E-FVI-FVISI-ICESt]
or
2ug/3.2ul
12.8 H₂O

Blunt
— 10 µM dNTP 12ul (10uM/each) + 2 ul Buffer B
14 ul H₂O + 4U/2ul Klenow, 25°C, 30 min; + EDTA → 10mM
Incativate Klenow by heating at 75°C, 10 min. phenol: Chloroform extraction
for Gene Clean)

Then + 2ul Not I, 37°C, 1 hr.

③ Run gel, cut bands, pool together,
Gene Clean. Elute in 40 ul

pSH1/s FVIS1-YM-E
+Not5 +Sal I

④ Ligation

Elutent 16ul + 2ul 10X Ligation Buffer
+ 2ul T4 ligase, 16°C, overnight.

pAdTrack-CMV
+ Not + EcoRV

pSH1/S-E-
FVI-FVISI
-ICESt
+Not I
+Sal I

pSH1/S-
FVISI
-YM-E
+Not I
+Sal I

⑤ Transformation

⑥ Miniprep with Qiagen Kit.

FIG 28

FIG-29

09/647418

JPEG image 511x431 pixels

FIG 30

FIG 31

EcoRI
BamHI
Sall
Smal
HindIII
Ncol
BamHI
BspEi
Smal
ApaLi
XhoI
SacII
NotI
BamHI
poly A
HA
AMP
111
Xmnl
16S intron
SRa promoter
HindIII

pSH1/S-Fvls1-Yama-E
(4661 bp)

FIG 32

Generation of Ad-GFP-CMV-YM-E
          Ad-GFP-CMV-E-ICE

① Co-transform E. coli BJ 5183 with pAdEasy-1 and pAdTrack-CMV-FvIs1-YM-E or pAdTrack-CMV-E-FV₁-EvIs₁-ICE st.

   a. Linearize the shuttle plasmids with Pme I
     µg of pAdTrack-CMV-FvIs₁-YME
       or pAdTrack-CMV-E-FV₁-EvIs₂-ICEst
     + 1 µl Buffer + H₂O → 9 µl, + 1 µl Pme I

   37°C, 2hr.
   phenol-chloroform extraction, ethanol precipitation and resuspend in 6 µl H₂O.

   B. Co-transformation: with 100 ng pAdEasy-1
            2 µl of BJ 5183
         2.0 mm cuvettes
       at 2580V, 200 Ohms, 25 µFD

  c. Selection:
     pick 10 smallest colonies, miniprep. check with Pac I.
     re transform XL1-Blue with the correct plasmid. miniprep. recheck with Pac I.
     Midiprep.
  d. Transfect 293 cells with Fugene.

    90% confluence 293 cells in 6-well-plate,
    4 µg plasmid/6 µl Fugene /well.

FIG 33

FIG 34

FiG 35

pAdEasy-1-Track-CMV-ICE-E
-YAMA-E

λ Hind III
ICE-1 + Pac I
+ BamHI
+ Pac I
+ BamHII

FIG 36

λ Hind III
YM-3.0
+ Pac I
+ Bam HI
YM-4.5
+ Pac I
+ Bam HI

09/647418

FIG 37 Generation of Ad-CMV-E-~~ICE~~ us 99/06799

Construction of pShuttle-CMV-E-Fvi-Fvls1-ICEsc
and Ad-CMV-E-ICE

① cut pshuttle-CMV with EcoRV + NotI

1μg/2μl (pshuttle-CMV) + 1μl Buffer H
+ 1μl EcoRV + 1μl NotI + H2O 5μl
37°C, 24h

② cut pSH/S-E-Fvi-Fvls1-ICEsc with
NotI + EcoRI (cut E-Fvi-Fvls1-ICEsc)

3μg/4μl + 3μl Buffer H + 3μl EcoRI
+ H2O 21μl, 37°C, 1h

Blunt
+ 10mM dNTP 18μl (1.8mM/each) + 3μl Buffer 3
+ 3μl H2O + 7μl T4 DNA Polymerase 25°C, 30';
+ EDTA → 10mM; 75°C, 10'
phenol: chloroform extraction (twice)
ethanol precipitation → 24μl H2O

Then
+ 3μl Buffer H + 3μl NotI
37°C, 24h

③ Run Gel, cut bands, pool together,
GeneClean, Elute in 40μl H2O

④ Ligation

Elution 16μl + 2μl 10X Ligase Buffer
+ 2μl T4 Ligase 25°C overnight

⑤ Transformation

⑥ Miniprep + Restriction Enzyme checking

⑦ cut pshuttle-CMV-E-Fvi-Fvls1-ICEsc with PmeI (½ of a miniprep), Cotransform E. coli BJ5183 with
100 ng pAd Easy-1. Miniprep + pacI checking (photo above)
⑧ Chose #2, retransform XL-1 Blue, Miniprep, +pacI; Midiprep, +pacI checking (small photo abo

FIG 38

Fig 39

(3/ 647418

FiG 40

Luciferase Assay of pShuttle – CMV
– FV₁ – FVAS1 – ICE – E   0104 – 010799

① 1 X 10⁵ JD-2⁰¹ cells / well (6 well – plate)
   in 1840 RPMI media with 5% FCS
   incubate 24 hrs

② Transfection : 2 µg pGL₂   2 µg ICE   per well
                 FuGene 2ul / µg DNA

   Incubate 6hrs . add AP1903 at 50 nM.

   Incubate 24 hrs.

③ Lysis — Luctometer

```
                8 JAN 99   AM 10:59              V. 1.1

                MEAS. TIME(s) :      15.0

                SAMPLE        RLU        % C.V.
                  1 1         294
                  1 2         291                 Control
                MEAN          292         0.8

                  2 1     2681958
                  2 2     2769999
                MEAN      2725979        2.3 Control + pGL₂

                  3 1      298762
                  3 2      223711
                MEAN       216237        4.9 pGL₂ + ICE

                  4 1       22084
                  4 2       22859
                MEAN        22471        2.4 pGL₂ + ICE + AP1903
```

FIG 41

JD-2α, T-C₂, T-C₂G, LNCaP — Adeno-YM or Adeno-ICE

① Plating cells: 24 well-plate

JD-2α — 20000/well

T-C₂ }
T-C₂G } 10000/well } in 1ml RPMI 1640 Media (5% FBS)

LNCaP — 30000/well → in 1ml DMEM Media (+5% FBS, 5% Nuserum, Insulin DHT)

incubate JD 24 hrs   Cell number doubling — 40000
T-C₂, T-C₂G — 48 hrs.   — 40000
LNCaP — 72 hrs   — 60000

② Infection:

For JD: ICE 1×10⁷ iu/ml   MOI   1   2   4   8   16
                            Add   4   8   16   32   64 ul

         YM 2×10⁷ iu/ml   MOI   2.5   5   10   20   40
                                   5   10   20   40   80 ul

                                  1:10

For T-C₂   ICE 5×10⁷ iu/ml MOI   2.5   5   10   20   40
   +T-C₂G   Add   2   4   8   16   32

           YM 5×10⁷ iu/ml   MOI   2.5   5   10   20   40
                            Add   2   4   8   16   32

   For LNCaP   3   6   12   24   48

After 4 hrs. Add AP 1903 → 50 nM, incubate 24 hrs.

③ Fix with 1% Glutaraldehyde — PBS, 15';
Stain 0.5% Crystal violate, 20';
Wash with H₂O, 30';
Resolve with Sorenson's Solution, 200 ul/well, 5';
Transfer 100 ul to each well of 96-well plate. Read OD at 570 nM.

T-C2G Cells Treated with Ad-YAMA or Ad-ICE + AP1903 or AP20187


FIG 42

T-C2 Cells Treated with Ad-YAMA or Ad-ICE + AP1903 or AP 20187

FIG 43

FIG 44

09/647418

LNCaP Cells Treated with Ad-YAMA or Ad-ICE + AP1903

FIG 45

09/647 18

Western Blot   1103 - 11049...

243 cells infected with Ad-YM or Ad-ICE

9% Resolving Gel ; Transfer — 400 mA, 2hrs.

1:1000   α-HA11 — 1st Ab.

1 Ad-YM3
2   ",   + 1903 (100 nM)
3   ",   + 2-D-DCB (100 nM)
4   ",   + Both

5 Ad-ICE
6   ",   + 1903
7   ",   + 2-D-DCB
8   ",   + Both

9 Ad-YM4
10   ",   + 1903
11   ",   + 2-D-DCB
12   ",   + Both

Expression and Activation of ICE and YM

FIG 46

FIG 47

09/647418

ADV-FKBP/ICE effectively kills
PC-3 prostate cancer cells

MOI: 0 0 2.5 2.5 5 5 10 10 20 20 40 40
AP1903
(50 nM) + + + + + + +

FIG. 43

ADV-FKBP/ICE effectively kills JD-2a BPH cells

FIG. 19

Treatment of s.c. prostate adenocarcinoma in situ with CID-inducible caspases

Day 0: Inject 2 x 10⁶
TRAMP-C2 cells (s.c.)

Day 12: Inject ~10¹⁰ pfu
ADV-GFP/F$_v$2-Casp1 (i.t.)

50-100 mm³

Day 16: Inject 50 µg
C.I.D (i.p.)

Analysis: resect tumor, H&E, TUNEL, anti-GFP

FIG 50

09/647418

*ADV-FKBP/ICE effectively kills TRAMP-C2 cells in vivo*

Fig 51

# ADV-FKBP/ICE + CID very effectively kills TRAMP-C2 cells in vivo

Fig 52

INVENTOR DECLARATION	Attorney Docket No. P01934US1

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **"REGULATED APOPTOSIS USING CHEMICALLY INDUCED DIMERIZATION OF APOPTOSIS FACTORS"**, the specification of which

(check one)   ☐   is attached hereto.

           ☒   was filed on 30 March 1999 as PCT international application No. US99/06799
                   and was amended on   21 June 2000
                                       (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority Claimed

(Number)	(Country)	(Day/Month/Year Filed)	☐ Yes	☐ No
(Number)	(Country)	(Day/Month/Year Filed)	☐ Yes	☐ No

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:

60/079,831   30 March 1998
(Application Serial No.)   (Filing Date)

(Application Serial No.)   (Filing Date)

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and insofar as the subject matter of each of the claims of this application is not disclosed in the prior U.S. or PCT international application in the manner provided by the first paragraph of Title 35, U.S.C. §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Sole or First Inventor David M. Spencer	Inventor's Signature		Date 9-29-00
Residence 810 Marston Street, Houston, Texas 77019 7300 BROMPTON #5723 Houston, TX 77025 TX		Citizenship US	
Post Office Address Same as above			

Full Name of Second Inventor Kevin M. Slawin	Inventor's Signature		Date 9-29-00
Residence 6560 Fannin Street, Houston, Texas 77030 TV		Citizenship US	
Post Office Address Same as above			

Full Name of Third Inventor	Inventor's Signature		Date
Residence		Citizenship	
Post Office Address			

Full Name of Fourth Inventor	Inventor's Signature		Date
Residence		Citizenship	
Post Office Address			

Full Name of Fifth Inventor	Inventor's Signature		Date
Residence		Citizenship	
Post Office Address			

Full Name of Sixth Inventor	Inventor's Signature		Date
Residence		Citizenship	
Post Office Address			

Full Name of Seventh Inventor	Inventor's Signature		Date
Residence		Citizenship	
Post Office Address			

Full Name of Eighth Inventor	Inventor's Signature		Date
Residence		Citizenship	
Post Office Address			